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High-risk human papillomavirus (hrHPV)-driven carcinogenesis is the predominant 
etiologic factor in oropharyngeal squamous cell carcinoma (OPSCC). Most HPV-positive 
OPSCCs respond well to therapy, prompting interest in reducing treatment intensities, but 
approximately 20% fail to respond to therapy and recur for unknown reasons.  The 
prognostic value of HPV in OPSCC warrants a universal standard for hrHPV assessment, 
and evaluation of factors that may differentiate responsive from non-responsive tumors is 
needed to determine the optimal treatment for patients. 
We compared hrHPV detection by PCR-MassArray, p16INK4a immunohistochemistry, 
and HPV in situ hybridization in oropharynx, nasopharynx, and oral cavity tumors to 
determine the optimal assessment of hrHPV.  HPV copy number, viral oncogene expression, 
integration sites, and integration transcripts were examined in seven HPV-positive HNSCC 
cell lines from patients who progressed, plus five responsive and five recurrent OPSCC 
tumors. 
Using combined PCR-MA with L1 consensus PCR and sequencing for resolving 
discordant results, we found PCR-MA to have the greatest sensitivity and specificity of the 
methods evaluated, making it optimal for HPV detection in combination with p16 for 
correlative viral activity.  Of 338 tumors, 183/212 (86%) of oropharynx, 9/18 (50%) of 
nasopharynx and 28/108 (26%) of oral cavity tumors were positive for hrHPV.  
All of the HPV-positive cell lines and tumors evaluated expressed HPV E6 and E7 




HPV-positive cell lines, which came from non-responsive outlier tumors, and the five 
recurrent tumors exhibited HPV integration into cancer–associated cellular genes.  Each of 
the responsive tumors demonstrated viral integration into non-genic chromosome regions, 
with only one integration into a cancer-related gene.  Integration transcript analysis 
revealed HPV-cellular fusion transcripts, intact cellular transcripts, and several genomic 
rearrangements, indicating genomic instability in the cell. 
We propose that viral integration is an early carcinogenic event, associated with 
disruption of the E1/E2 region and alternate E6*I transcription, leading to increased viral 
oncogene expression as the carcinogenic driver in responsive tumors.  Further, we 
hypothesize that HPV integration into cellular genes may result in secondary alterations in 
cellular gene expression or dysfunction, resulting in a more aggressive malignant 










Human Papillomavirus  
History: Human papillomaviruses (HPVs) belong to a family of small DNA viruses, 
all having a circular double-strand DNA genome of approximately 8kb. Papillomaviruses 
are species-specific and infect cutaneous or mucosal keratinocytes in mammals as well as 
several amniotes.  More than 100 unique HPV types have been identified; clinical 
manifestations include benign warts, papillomas, condylomas, and less frequently, 
mucocutaneous malignancies.  
Animal papillomaviruses have been studied as models of HPV infection and disease 
etiology. Bovine papillomaviruses, BPV1-10, are members of the delta-, epsilon-, and xi-
papillomaviruses, transmitted by direct and indirect routes including flies, fence posts, and 
halters1,2.  BPVs produce mucosal and cutaneous lesions in cattle, which are typically 
benign,  but in some cases become malignant, particularly in bladder and upper 
gastrointestinal lesions in association with exposure to bracken fern, an environmental 
carcinogenic cofactor2,3.  Early molecular examination of BPV supported subsequent 
characterization of human papillomavirus types4. 
Cottontail rabbit papillomaviruses (CRPVs) are members of the kappa genus of 
papillomaviruses, and cause warty cutaneous growths on animals infected with the virus.  
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CRPV transmission is both direct between animals and indirect through arthropod 
vectors5.  CRPV was discovered as the first DNA tumor virus by Richard Shope in 19336, 
and has been widely studied since then as a model of carcinogenesis. CRPV in rabbits was 
used to study virus-mediated carcinogenesis in association with host immune response7, 
exposure to chemical carcinogens8,9, and host major histocompatibility complex (MHC) 
class II haplotype10. 
The infectious nature of human skin and genital warts was recognized in the 19th 
century, and wart contagion was reported by Payne in 189111.  The causative “human wart 
virus” was confirmed in the early 1900s, and the double-strand DNA (dsDNA) circular 
genome was characterized in 196512,13. Throughout the 1970s, studies were performed 
examining viral DNA and RNA isolated from different types of warts.  Hybridization and 
endonuclease restriction digest experiments demonstrated the heterogeneity and diversity 
of human papillomavirus types.  Much earlier, in 1842, Rigoni-Stern published his 
observation that cervical cancer rates were much higher in sexually active women than in 
virgins and nuns, and suggested that cervical cancer was associated with sexual contact4. 
Many studies to establish a link between cervical cancer and sexually transmitted 
infections (particularly Herpes simplex type 2) followed, but none were successful.  It was 
not until the 1970s that researchers began studying the possible association between 
human papillomaviruses and cancer, based in part on sporadic instances of genital wart 
transformation to squamous cell carcinoma4.  In 1976, Harald zur Hausen published his 
hypothesis implicating human papillomavirus as the causative agent in cervical cancer, and 
several years later he and others identified the novel types HPV6 in genital warts and 
HPV11 in laryngeal papillomas, followed by studies reporting HPV in invasive condylomata 
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acuminata14,15.  Using portions of known HPV types as probes, researchers were able to 
detect known types and isolate novel HPVs in studies of cervical cancer, and in 1983 and 
1984, zur Hausen and his collaborators specifically identified HPV16 and HPV18 in cervical 
tumors16,17.  The first epidemiological study on the association between cervical cancer and 
HPV was published in 1987, comparing HPV positivity (HPV 6, HPV11, HPV16 and HPV18) 
with cytological findings in nearly 10,000 cervical specimens18.  
Biology: The human papillomavirus life cycle begins with infectious virion particles 
gaining access to epithelial basal lamina, where the virus infects basal cells.  The host cell 
machinery is used to replicate viral genes along with the cellular genome, increasing the 
number of infected calls and producing multiple episome copies that are maintained in the 
basal layer. As the HPV-infected keratinocytes differentiate and move toward the epithelial 
surface, different viral genes are expressed, allowing high viral genome amplification and 
the expression of the late region genes that encode the viral capsid proteins. As the cells 
reach the surface, the HPV episomes are packaged within the capsids for final viral 
assembly and release. 
When HPV infects oropharyngeal squamous epithelium, the virus typically enters 
basal cells in the crypt epithelium overlying the lymphoid tissue of the tonsils (Figure I.1).  
Initially, the virus induces replication of the infected cells and along with it, replication of 
the viral genome, resulting in release of infectious virus.  Eventually, the infection becomes 
latent and no infectious virus is produced, although HPV DNA can be detected in 




Figure I.1.  Schematic Representation of hrHPV Oncogenesis in the Oropharynx.  
with HPV E6 and E7 oncogenes driving carcinogenesis. HPV-induced tumor behavior may 
be influenced by viral type, copy number, or physical status, as well as splicing of the E6 
oncogene or where HPV integration occurs in the host cell genome (Figure I.1).   
Viral genome: Human papillomaviruses have a circular dsDNA genome of 
approximately 8kb, with an upstream regulatory region (URR) and eight open reading 
frames (ORFs) (Figure I.2). The ORFs are divided into early (E1, E2, E4, E5, E6 and E7) and 
late regions (L1 and L2).  In a productive high-risk HPV (hrHPV) infection, a polycistronic 
messenger RNA is produced, resulting in early region protein expression.  E6 and E7 
proteins subvert cell cycle control primarily by respectively inhibiting p53 and 
Retinoblastoma (Rb) protein function.  HPV E7 binds to Rb, sequestering it and allowing 
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 Figure I.2.  Genome Organization of HPV16.  
 
the E2F family of transcription factors to induce expression of genes that drive the cell into 
the cell cycle. In high-risk HPVs, E7 also targets Rb for ubiquitin-mediated degradation, 
resulting in sustained cell cycle progression.  HPV E6 recruits the ubiquitin ligase E6-
Associated Protein (E6AP)19 to p53, thereby removing p53-mediated control of the cell 
cycle and p53-mediated gene expression. In high-risk HPVs, the E6 interaction with E6AP 
and p53 results in polyubiquitination, export from the nucleus, and proteasomal 
degradation of p53.  HPV E1 and E2 proteins complex with the host cell polymerase and the 
viral DNA to drive replication of the viral genome in the infected cells, resulting in 
production of multiple episomal copies of virus.  The HPV E2 protein is also a 
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transcriptional repressor of E6 and E720, which allows the infected cells containing 
multiple copies of the viral genome to differentiate, express L1 and L2 capsid proteins, and 
package the viral episomes, creating infectious virus that are released to infect another cell 
or another host (Figure I.1).  
Oncogenesis: The E6 and E7 proteins of the hrHPV types differ from those of the 
low-risk, non-oncogenic HPV (lrHPV) types and more effectively disrupt the critical cellular 
growth control mechanisms maintained by Rb and p53, such that infection with hrHPV can 
lead to malignant transformation19,21-24.  E7 binding to Rb allows E2F-driven expression of 
S-phase genes. E7 also inhibits the cyclin-dependent kinase (CDK) inhibitors p27 and p21, 
deregulating cyclin/CDK complexes that drive progression through the cell cycle and 
unrestricted cellular proliferation.  Considering the large proportion of the population that 
is infected with hrHPV25, malignant transformation is comparatively rare, and hrHPV 
infections are usually cleared within 1-2 years26.  However, genomic instability from 
impaired p53 function combined with the unrestricted proliferation induced by the viral 
oncogenes leads to malignant transformation in a subset of cases.   
Most hrHPV-induced cancers are driven by the viral oncogenes and HPV-positive 
tumor cell lines are dependent on E6 and E7 expression for proliferation and survival27-29.  
Most HPV-positive tumors respond well to therapy, but some do not30-40.  The factors that 
differentiate such tumors are poorly understood.  Viral integration into the host cell 
genome is common and may increase risk of cancer by disruption of E2 and higher 
expression of E6 and E741,42.  The low-risk HPV viral oncogenes lack transforming ability 
and typically cause benign tumors such as vaginal condylomas and laryngeal papillomas, 
but in rare cases low-risk viruses can lead to malignant transformation43,44. In some cases 
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integration of low-risk types into a host gene results in gene fusion or disruption of the 
cellular gene and invasive cancer43,45-49 
Viral copy number: Pre-invasive cervical lesions with high viral copy number are 
reported to be more likely to progress to invasive cancer50. Perhaps multiple copies lead to 
higher expression of the viral oncoproteins, reduced control of cell replication machinery, 
more frequent cell division, more replication errors, and a greater chance for integration, 
disruption of E2, and the development of tumors. Viral integration is implicated in 
progression from cervical intraepithelial neoplasia (CIN) to invasive cancer in cervical 
lesions 51. Integration is thought to increase the risk of malignant transformation through 
disruption of E2 and upregulated expression of E6 and E7 oncogenes52 as has been 
observed in HPV-positive cervical cancer cell lines50,53 and tumors41,54. Nevertheless, Gray 
et al. report progression to cancer in HPV16 episome-only containing epithelial cells55. Our 
preliminary data34, and that of Hafkamp et al56, and Holzinger, et al.57 suggest that high 
numbers of viral episomes in oropharyngeal cancer are associated with better response to 
treatment40.  It is not known if high episomal viral copy number is sufficient for malignant 
transformation in oropharyngeal cancer. Hafkamp et al. reported that only 41% of HPV-
positive oropharyngeal carcinomas have integrated HPV56,58. Thus, high copy episomal 
number, as occurs in a productive infection, may be associated with increased risk of 
transformation.  We postulate that HPV-positive tumors with high episomal copy 
numbers40,57 likely represent the early evolution of the cancer, and consequently better 




Figure I.3.  Illustration of HPV16 E6 Splicing. 
 
 
Alternate transcription: The HPV genome is transcribed as a polycistronic pre-
mRNA with overlapping ORFs. High-risk HPV E6 and E7 oncogenic proteins are drivers of  
malignant transformation.  The E6-E7 transcript has two potential introns, each with three 
possible 3’ splice sites (Figures I.3 and I.4), resulting in multiple coding possibilities59.  HPV 
transcript splicing is only seen in high-risk HPV types, suggesting that the splice variants 
are involved in HPV oncogenesis60.  The E6 oncogene is expressed as full length or as 
alternate transcripts designated E6*I and E6*II.  Alternate E6* expression has been 
implicated in oncogenesis 42,52,61 and may be related to viral integration and/or loss of 
regulation by E2 41,61,62.  In cervical specimens, high expression of virus63 has been linked to 
high-grade CIN and cervix cancer, respectively61.  HPV E6 alternate splice forms may be a 
surrogate for the transition from episomal only to integrated virus in the oncogenic 
pathway.  The alternate E6 splice forms may also alter p53 degradation and influence 
response to therapy in a dichotomous manner.  The solution structure of full length E6 
dimers was recently elucidated and dimerization was shown to be required for E6-
mediated p53 degradation initiated by ubiquitination by E6AP64. The amino acids of the E6 




Figure I.4.  Amino Acid Sequence of Alternate E6 Oncoproteins. Dimerization amino acids 
are shown in red.  E6*I and E6*II lose the F47 residue (circled in blue) that is essential for E6 
dimerization. 
F47) are shown in red in Figure I.4.  Phenylalanine at amino acid 47 (F47) is essential for 
E6 dimerization and p53 degradation65-67.  We compared the amino acid sequences of full 
length E6 to E6*I and E6*II (Figure I.4).  Critical amino acids necessary for dimerization 
including D44, A46, and F47 are absent in E6*I and E6*II, suggesting that the E6 splice 
variants are less able to dimerize and less able to induce p53 degradation. The effect of the 
alternate E6 variants on p53 expression and degradation has not been characterized.  In a 
previous study we found that many HPV-positive that oropharyngeal squamous cell 
carcinoma (OPSCC) cells overexpress wild type p5334.  E6 alternate transcripts unable to 
dimerize and recruit E6AP for ubiquitination of p53 may allow retention of p53 functions 
such as induction of apoptosis or cell cycle arrest and DNA repair.  If p53 is functional in 
HPV-positive tumors that express the alternate transcripts, p53-induced apoptosis could 
explain the high response rate of HPV-positive oropharynx tumors to chemotherapy and  
radiation30,31,33-40. However, if the apoptotic pathway is blocked, functional p53 can induce 
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cell cycle arrest and DNA repair resulting in resistance to chemoradiation (ChemoRT)68.  
We reported that high EGFR expression and the combination of wild-type p53 and high Bcl-
xL expression are linked to poorer survival in HPV-positive OPSCC34.  EGFR up-regulates 
Bcl-xL which blocks apoptosis69-71. Together, wild type p53 and elevated Bcl-xL are 
associated with resistance to chemotherapy in vivo and in vitro33,34,68,72,73.  Accordingly, if 
E6*I and E6*II fail to degrade p53, wild type p53 and anti-apoptotic Bcl-xL can result in 
ChemoRT resistance via p53-mediated arrest and repair34,68. The HPV E7 oncogene is 
considered to be the dominant transforming gene in HPV-induced tumors74,75. Some 
studies suggest that E7 is expressed exclusively from spliced E6*, and never from full 
length E6, which is the transcript that produces the functional E6 oncoprotein24,60,76-81. 
Other studies describe E7 oncoprotein translation from full length and spliced E6 in 
cervical cancer cell lines, as well as detection of the different splice profiles in cervical pre-
cancerous lesions, tumor specimens and cell lines82,83. The ratio of E6*I to full-length E6 
transcript was reported to correlate with increased levels of E7 transcript and E7 protein 
in HPV-positive cervix cancer cell lines76, which are derived from tumors that fail to 
respond to therapy. The relationship between E6* expression, E7 expression, and response 
to treatment in head and neck cancers has not been studied.   
Integration: HPV-positive OPSCC tumors are driven primarily by the powerful viral 
oncogenes E6 and E774, yet these tumors generally respond well to therapy32, suggesting 
that patients with HPV-positive tumors that do not respond may have additional factors 
that lead to their worse outcome, but these factors are unknown. Two studies have shown 
that viral integration can lead to viral host fusion transcripts46,84.  The low-risk HPV viral 
oncogenes lack transforming ability, yet there are examples of cancer developing in 
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patients with HPV6-46 or HPV11-induced45,85 laryngeal papillomas. Integrated HPV6a has 
been identified in tonsillar carcinomas44,47 and the carcinogenic mechanism linked to viral 
integration into the cellular genome. Viral-cellular fusion transcripts and disruption of 
cellular genes are also reported for hrHPV types84.  There is a controversy in the HPV 
literature about the role of cellular gene disruption by integration.  Studies in early cervix 
lesions report that HPV integration is a stochastic event with random sites of integration, 
often in fragile sites or regions of active chromatin and highly transcribed genes57,86.  In 
such early lesions there are few examples of HPV integration affecting cellular genes86.  
However, in more advanced tumors, such events might be important. In the HPV68-
containing ME180 cervical cancer line, viral integration resulted in inactivation of APM-1, a 
putative tumor suppressor gene. Re-expression of APM-1 inhibited growth of HPV-positive 
cell lines HeLa and CaSki28.  HPV insertion near c-myc has been observed in several cases29. 
HPV-positive anogenital lesions with integration in transcribed genomic regions also had 
HPV-oncogene-cellular gene fusions in 15 of 19 carcinomas87. This suggests that viral 
integration can interrupt expression of genes that control cellular behavior, or viral-host 
gene fusion can result in elevated expression of a gene that drives a cancer phenotype. 
Recent observations from TCGA (The Cancer Genome Atlas) consortium support this 
hypothesis. Of 30 HPV-positive head and neck squamous cell carcinoma (HNSCC) tumors, 
three (10%) that have been analyzed exhibit cellular gene disruption. In one tumor, HPV 
integrated in RAD51B, an essential gene for DNA repair, suggesting that the disruption of 
RAD51B contributes to the progression of this tumor.  Two other HPV-positive cancers 
examined by exome analysis had HPV-ETS gene fusion transcripts. This is intriguing 
because ETS transcription factor family fusions are drivers and prognostic markers of poor 
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outcome in prostate cancer43,48,49 and Ewing’s sarcoma55,88.  These are also targets of 
therapies being used to interfere with ETS family fusions43,89.  Therefore, it is important to 
examine HPV integration in HNSCC.   
Classification of types: Human papillomaviruses were originally grouped together 
with closely-related polyomaviruses in the family Papovaviridae based on common 
characteristics, including a double-strand circular DNA genome and non-enveloped capsid.  
However, these viruses have since been classified into separate families, Polyomaviridae 
and Papillomaviridae, due to dissimilar genome size and organization and lack of sequence 
homology. The taxonomy of the Papillomaviridae family is based on sequence comparisons 
of the L1 ORF, which is the most conserved among papillomaviruses90-94 (Figure I.5).  The 
human papillomaviruses include alpha, beta, gamma, delta, mu, and nu genera; those with 
at least 40% homology in the L1 ORF are classified in the same genus (α, β, ɣ, µ & ν). Within 
genera, HPV species are distinguished by number, share common biological and 
pathological properties, and demonstrate 60-70% L1 sequence homology. Perhaps best 
recognized as they relate to human disease are specific HPV types; there are currently over 
170 sequenced and classified human papillomavirus types, as well as many additional 
candidate types yet to be validated. An HPV type is considered unique if the L1 ORF differs 
at least 10% from the closest known type, HPV subtypes are 2-10% different, and variants 
are <2% different from the closest known type. 
Alpha-papillomaviruses infect mucosal and cutaneous epithelium in humans and 
primates, include high- and low-risk viruses, and share a conserved genome containing the 
E5 ORF, which is absent in some of the other genera. Alpha-papillomaviruses contain 15 




Figure I.5. HPV Phylogenic Tree Based on L1 Sequence Homology. Adapted from de Villiers, 
E. M. et al. Virology (2004), and White, E. A. and Howley, P. M. Virology (2013). 
Species 4 includes HPV2, HPV27, and HPV57, and infection generates common skin warts. 
HPV26, HPV51, HPV69, and HPV82 are high- and low-risk mucosal types and belong to 
species 5. Similarly, species 6 contains high- and low-risk mucosal types HPV53, HPV30, 
HPV56, and HPV66. Species 7 is comprised of high-risk mucosal HPV18, HPV39, HPV45, 
HPV59, HPV68, and HPV70. Species 8 includes low-risk mucosal and cutaneous types 
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HPV7, HPV40, and HPV43. The most frequent causal factor in cervical cancer, HPV16 
belongs to species 9, along with other high-risk mucosal types HPV31, HPV33, HPV35, 
HPV52, HPV58, and HPV67. Finally, species 10 is comprised of low-risk mucocutaneous 
HPV6, HPV11, HPV13, HPV44, and HPV74; these types cause benign laryngeal papillomas, 
genital warts, and condylomata acuminata, and may become malignant in rare instances.   
Beta-papillomaviruses infect cutaneous epithelium in humans, generating mostly 
benign, but occasionally malignant lesions. These viruses are frequently latent, but become 
activated in immunosuppressed individuals. The E5 ORF is lacking in this genera. There are 
45 HPV types among the 5 β-papillomavirus species.  Species 1 and 2 are together referred 
to as EV HPV types, due to their association with Epidermodysplasia Verruciformis (EV); 
these types include HPV5, HPV8, HPV9, HPV12, HPV14, HPV15, HPV17, HPV19, and others.   
Gamma-papillomaviruses infect human cutaneous epithelium, producing benign 
lesions that are distinguishable by histological detection of intracytoplasmic inclusion 
bodies. The viruses in this genus also lack the E5 ORF, and are grouped into 5 species. The 
most common of the 54 ɣ-papillomavirus types are HPV4, HPV48, HPV50, HPV60, HPV65, 
HPV88, HPV95, and HPV99.   
The mu-papillomaviruses are specific for cutaneous human epithelium and cause 
benign foot warts, which contain viral type-specific intracytoplasmic inclusion bodies. 
Genomes of viruses in this genus have relatively large URRs. Each of the two µ-
papillomavirus species has only a single HPV type, discernible by the length of the URR; 
HPV1 (982bp URR) is a member of species 1, and HPV63 (558bp URR) is a member of 
species 2.   
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The nu-papillomavirus genus is comprised of single species and type, HPV41, 
originally isolated from a facial wart95. The nu-papillomavirus causes benign and malignant 
cutaneous lesions in humans, as evidenced by the detection of HPV41 in warts, skin 
carcinomas, and premalignant keratoses96. The HPV41 genome is unique in that it contains 
several large, uncharacterized ORFs, and has modified E2 binding sites in the URR.   
Evolution: Papillomaviruses are highly host-restrictive, suggesting “host-linked” 
evolution. However, exclusive co-evolution is precluded by 1) the phylogenetic separation 
of the 5 different genera of HPV (α, β, ɣ, µ & ν), 2) the phylogenetic position of non-human 
primate papillomaviruses within groups of human papillomaviruses, as opposed to basal, 
and 3) the phylogenetic incongruence between papillomavirus early and late gene 
sequences97,98. 
Recent phylogenic analysis has suggested that papillomavirus evolution is driven 
initially by host niche-specificity, followed by virus-host co-speciation. There are multiple 
mechanisms thought to influence this process, including gain and possible subsequent loss 
of early gene sequences or complete open reading frames and recombination98. In addition, 
viral speciation and generation of papillomavirus type variants are caused by lineage 
fixation, when sequential single-nucleotide polymorphisms (SNPs), insertions or deletions 
(INDELs) accumulate and become fixed in the genome99.  
High- and low-risk: In early experiments, the genome of hrHPV was shown to 
transform primary rodent cells (with activated ras), immortalize primary human 
keratinocytes, produce tumorigenic primary keratinocytes with activated ras, and alter 
differentiation of an organotypic raft culture, whereas lrHPV lacked these abilities100. The 




Figure I.6. Phylogenic Tree of Mucosal/Genital Alpha-Human Papillomaviruses. 
Organization based on early gene sequence homology. Most prevalent high-risk HPV16 and 
HPV18 outlined in blue and starred, most prevalent low-risk HPV6 and HPV11 outlined in 
orange.  Adapted from Burk, R. D. et al. Public Health Genomics (2009). 
 
activity and cellular interaction, demonstrated in multiple studies by in vitro transfection of 
E6 and E7100.  Early gene sequence analysis separates high-risk HPV types from two 
distinct groups of low-risk HPVs (Figure I.6). It is important to note the difference in 
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regulation of E6 and E7 transcription and translation between hrHPV and lrHPV that may 
affect expression levels of the oncoproteins.  High-risk HPV has a single promoter region 
upstream of E6, and produces a polycistronic mRNA, while lrHPV has promoter regions 
upstream of both E6 and E7. However, when early regions of both lrHPV and hrHPV were 
expressed from an identical strong promoter, only the hrHPV immortalized keratinocytes, 
and when high and low-risk E6 and E7 were separately expressed from the same promoter, 
the resulting lrHPV E6 and E7 protein products were determined to be non-oncogenic100. 
The major functional differences in high- and low-risk HPV oncogenes are 
summarized in Table I.1101,102.  High-risk HPV types have E6 splice variants that are not 
found in low-risk types; spliced transcripts are reported to produce higher levels of 
E724,60,76-81.  Studies comparing lrHPV and hrHPV E6 function demonstrate that both types 
inhibit p53 transactivation and acetylation, all high-risk but not all low-risk types bind to 
p53 and E6AP, and only high-risk has been shown to degrade p53102.  Other oncogenic E6 
functions that are exclusive to hrHPV include immortalization of Rb-inactivated human 
cells, inhibition of keratinocyte differentiation, telomerase activation, c-myc activation, and 
induction of genetic instability100. The hrHPV E6 oncoprotein contains a C-terminal PDZ 
binding domain, which functions to bind and degrade multiple tumor suppressor proteins 
such as DLG1, MAGI-1, and Scribble, while all but a few lrHPV types lack this motif103.  
There are similarities in hrHPV and lrHPV E6 function; both bind and degrade pro-
apoptotic BAK, both abolish cellular senescence induced by PML (promyelocytic leukemia), 
and both lrHPV and hrHPV E6 participate in mediating the transition from G1 to S in the 
cell cycle100.  The conserved functions of E6 in both lrHPV and hrHPV may be related to 




High-Risk HPV E6 Low-Risk HPV E6 
Alternate Transcription No Splicing 
E6*I, E6*II, E6*III Full Length E6 
Higher E7 Expression Lower E7 Expression 
Strong p53 Binding & Degradation Weaker p53 Binding, No Degradation 
DNA Damage= Evasion of Growth Arrest DNA Damage= Growth Arrest 
Inhibition of Apoptosis   
Degradation of PDZ-Domain Proteins No Interaction with PDZ Proteins 
Reduction in Tumor Suppressor Activity   
Telomerase Activation No Telomerase Activation 
Immortalization   
c-myc Activation No c-myc Activation 
Dysregulated Proliferation   
Life-Cycle Associated E6 Similarities 
Interaction with E6-Associated Protein 
Inhibition of p53 Transactivation and Acetylation 
  
High-Risk HPV E7 Low-Risk HPV E7 
Binding & Degradation of Rb Weaker Rb Binding, No Degradation 
Continuous Cell Cycle Progression   
Cell Survival   
Binding & Degradation of p107 Weaker p107 Binding, No Degradation 
Continuous Cell Cycle Progression   
p21 Binding Weaker p21 Binding 
DNA Damage= Evasion of Growth Arrest DNA Damage=  Growth Arrest 
Production of Genomic Instability No Genomic Instability 
Cellular Transformation   
Life-Cycle Associated E7 Similarities 
Targeting & Degradation of p130 
Binding of p600 
Activation of Cell Cycle and DNA Synthesis 
Binding of Rb for Cellular Proliferation 
 
Table I.1. Primary Functional Differences and Similarities in High- and Low-Risk Human 
Papillomavirus E6 and E7 Oncoproteins. Adapted from Doorbar, J. et al. Vaccine (2012) and 




The E7 oncoprotein produces genomic instability through a variety of mechanisms 
that are exclusive to hrHPV. High-risk HPV E7 induces cellular DNA synthesis at the G1 to S 
transition by binding and targeting Rb for ubiquitin-mediated degradation, disrupting the 
Rb-E2F complex and releasing the E2F transcription factor. This activity has been shown to 
be much greater in hrHPV E7 than lrHPV E7, which binds but cannot degrade Rb. The 
LXCXE protein domain of hrHPV E7 allows specific and high-affinity binding of additional 
members of the Rb family, p107 and p130, which are subsequently degraded, while lrHPV 
E7 binds these proteins with much lower affinity, and only degrades p130.  The hrHPV E7 
disruption of Rb-family complexes causes de-repression of many additional S-phase genes.   
Additional E7 functions that are present in hrHPV but lacking in lrHPV include activation of 
the c-fos and p73 promoters and STAT-1 suppression.  Furthermore, hrHPV E7 but not 
lrHPV E7 is able to bypass DNA damage- or differentiation-mediated growth arrest. This 
difference can be attributed to the inability of lrHPV E7 to degrade Rb and its lower affinity 
for p21 abrogation, both required for growth arrest evasion.  Functions of E7 shared 
between lrHPV and hrHPV are associated with the viral life cycle, including targeting and 
degradation of p130, binding p600, activation of cellular pathways for viral genome 
amplification, and low-level disruption of Rb for cellular proliferation100.   
 Disease: Human papillomaviruses have specific tropisms for infection of cutaneous or 
mucosal epithelium. The type of epithelium infected, together with the oncogenic potential 
of the HPV, determines the clinical presentation of the associated lesions. The four major 
categories of HPV involved in human disease (cutaneous benign, cutaneous malignant, 
mucosal benign, and mucosal malignant), are summarized in Table I.2. 
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 Cutaneous benign: Benign cutaneous HPV conditions include skin warts caused by 
HPV1, HPV2, HPV3, HPV4, HPV7, HPV8, HPV10, and HPV63.  Juvenile epidermodysplasia 
verruciformis, an autosomal recessive immune disorder associated with HPV infection is 
classified as benign cutaneous, causing plane warts (HPV3 and HPV10) and verrucous 
lesions (HPV5 and HPV8).   
 Cutaneous malignant: In adults, EV transitions to a malignant cutaneous condition, 
with squamous cell carcinoma developing in 30-60% EV patients by the age of 40104,105.  
This malignant transformation occurs in association with UV sun exposure and the primary 










Skin Warts  1, 2, 3, 4, 7, 8, 10, 11 
Epidermodysplasia 
Verruciformis  
3, 5, 8, 10 
Malignant 
Extra Genital Bowen's 
Disease 
6, 11, 27, 76 & other 
hrHPV 






Condyloma Acuminata 6, 11 
Laryngeal Papillomatosis 6, 11 
Bowenoid Papulosis 16, 18 & other hrHPV 
Malignant 
Genital Bowen's Disease 16, 31 
Anogenital Cancers 16, 18 & other hrHPV 
Head and Neck Cancers 16, 18 & other hrHPV 
 
Table I.2. Summary of HPV-Induced Human Disease. 
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cutaneous squamous cell carcinomas also occur independent of EV. These tumors are most 
frequently associated with UV sun exposure and caused by beta-HPV types107 and mucosal 
types HPV16 & 31108.  HPV-induced skin tumors are seen with much higher frequency in 
immunocompromised patients; a 200-fold increased incidence of squamous cell carcinoma 
(SCC) is reported in renal transplant recipients105, and the proportion of HPV-positive SCC 
in immunocompromised patients is 88-100%104,109,110.  Cutaneous SCCs are far less 
frequent in immunocompetant patients, and fewer (30-78%) are HPV-positive105,107.   
 Extra Genital Bowen’s Disease (EGBD) is a cutaneous squamous cell carcinoma in situ, 
and up to 5% of cases progress to invasive carcinoma104.  Both high- and low-risk HPV 
types have been associated with EGBD111. 
Mucosal benign: Focal epithelial hyperplasia (Heck’s disease) is a benign mucosal 
condition caused by HPV13 or HPV 32, and presents with multiple pink papules on the oral 
mucosa104.  Condylomata acuminata (anogenital warts) are most commonly caused by 
HPV6 or HPV11, although other low-risk types, and occasionally high-risk HPV types have 
been detected, and 10-15% of lesions contain multiple HPV types104.   
Laryngeal papillomatosis (recurrent respiratory papillomatosis) is associated 
primarily with HPV6 and HPV11, with fewer than 5% of cases attributed to other types112.  
This condition is characterized by persistent growth of papillomas in the larynx; juvenile 
prevalence is linked to maternal genital warts during pregnancy and delivery113.  In 
approximately 16% of cases (primarily associated with HPV11), recurrent respiratory 
papillomatosis can spread to the bronchi and lungs, and of these, 1-7% develop pulmonary 
malignant transformation85,114,115.  Rare cases (2%) of malignant conversion outside of 
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pulmonary involvement have been reported, and have been associated with either lrHPV6 
viral integration46 or lrHPV11 infection45,85.  
Bowenoid papulosis is characterized by anogenital papular lesions classified as 
undifferentiated intraepithelial neoplasia. HPV16, HPV18 and other hrHPV types are 
detected in 66.7% of cases108,  and malignant transformation is rare (2-3%)104. 
Mucosal malignant: The most prevalent malignant HPV-related disease involves 
the mucosal epithelium of the anogenital region. Genital Bowen’s disease is a condition of 
genital carcinoma in situ, most commonly associated with HPV16116, but HPV31 has also 
been detected108.  Vulvar cancer is fairly uncommon, representing only 3% of worldwide 
gynecological cancers104.  High-risk HPV was detected in 97.1% of vulvar intraepithelial 
neoplasia 3 (VIN3) cases, and in 68.8% of invasive vulvar cancer (IVC), with the majority of 
HPV-positive cases identified as HPV16117,118.  Vaginal and penile cancers were 60-90% and 
30-70% HPV-positive, respectively, with HPV16 the prominent type detected118-120. The 
HPV type distribution of anal cancer, 80-96% of which are HPV-positive, has been reported 
to be 70% HPV16, 5% HPV18, and remaining 25% HPV6, HPV31, or HPV33104,118. High-risk 
HPV is a necessary cause in 100% of cervical cancers, and 61% are induced by HPV16, with 
the remaining HPV-positive cases identified as non-HPV16 high-risk types or multiple 
infections121-124.  No significant difference in odds ratio was seen for infection with multiple 
HPV types compared to infection with a single type, although the highest odds ratio 
reported was for multiple-type infections that include HPV16121.  Smoking is a significantly 
associated carcinogenic risk factor for HPV-positive, but not HPV-negative, vulvar and 
vaginal squamous cell carcinomas125.  Additionally, smoking is a cofactor in the progression 
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of HPV-positive, low-grade squamous intraepithelial lesion (LSIL) to high-grade squamous 
intraepithelial lesion (HSIL) and cervical cancer126.  
Head and neck cancers are also associated with mucosal HPV.  Among head and 
neck tumors, OPSCC is most frequently associated with hrHPV. The worldwide proportion 
of HPV-positive oropharyngeal tumors is increasing; prior to 2000, 40.5% of OPSCC were 
HPV-positive, and this has increased to 72.2% between 2005 and 2009127, and in our recent 
study, we found 83% of OPSCC to be HPV-positive128. Among the HPV-positive oropharynx 
tumors, 80-90% contain HPV16124,128.  Although the basis for this disparity is not 
understood, HPV-positive oropharynx tumors respond better to therapy than HPV-negative 
tumors, and patients with HPV-positive tumors have better outcome than patients with 
HPV-negative OPSCC30,32-40. 
The predictive value of HPV in non-oropharynx HNSCC is largely unstudied, likely 
due to the far lower proportion of HPV-positive tumors at these sites128. A recent study by 
Isayeva et al. reported the weighted prevalence of HPV-positive tumors in non-oropharynx 
HNSCC as 20.2% in oral cavity tumors, with HPV16 the most common type detected; 23.6% 
in larynx tumors, again HPV16 was most frequently detected, but larynx tumors contained 
a much greater diversity of hrHPV types than oral cavity or oropharyngeal tumors; 29.6% 
in sinonasal cancers; 20.5% in nasopharyngeal cancers; and 47% in salivary neoplasias 
(mucoepidermoid carcinomas), which all contained HPV16, HPV18, or both129.  
Patients with HPV positive head and neck tumors are far more likely than patients 
with HPV-negative tumors to be non-smokers34,130.  However, in our own data we observed 
that over two thirds (68%) of patients with HPV positive tumors were tobacco users and 
that current tobacco users were significantly more likely to suffer recurrence than never-
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users (Hazard Ratio= 5.2, Confidence Interval 1.1-24.4; significance, p=0.038)36. Tobacco 
use (synergistic with alcohol use) persists as the predominant etiologic factor in HNSCC 
tumors that are negative for HPV131-133. 
 
Head and Neck Squamous Cell Carcinoma 
Epidemiology: In a recent comprehensive examination of oral HPV infection in the 
United States25, the prevalence of oral HPV infection in adults was 6.9%, hrHPV was 3.7%, 
and HPV16 was 1.0% (men and women, 14-69 years old). Men were more likely to have 
oral HPV infection than women (10.1% and 3.6% respectively), and prevalence by age 
distribution showed bimodal peaks at 30-34 and 60-64 years old, with the highest 
prevalence at 55-64 years old.  The transmission of HPV through sexual contact is 
demonstrated by the significant association of HPV infection and reported sexual activity, 
categorized and reported as any sex, vaginal sex, oral sex, and anal sex.  Prevalence of oral 
HPV was more than 8-fold greater in those reporting any sexual history than those 
reporting no sexual history. The prevalence of oral HPV infection increased in association 
with number of past or recent sexual partners, reaching a maximum oral HPV prevalence of 
20% among those reporting greater than 20 lifetime sexual partners25. The direct 
relationship between oral HPV infection and lifetime number of oral sex partners has been 
demonstrated in multiple studies, and an analysis of concurrent oral and genital HPV 
infection and HPV-type concordance in women together demonstrate the multidirectional 
transmission corridors between anogenital and oral HPV infections25,134,135.  
HPV detection methods: The incidence of cervical cancer is in a state of steady 
decline, due to routine cytological screening, histological biopsy assessment, and hrHPV 
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testing, all leading to diagnosis and treatment of early lesions124.  Unfortunately, there are 
currently no equivalent methods for early detection in HNSCC. With the increasing 
prevalence of hrHPV in HNSCC and the predictive value of hrHPV in tumor response to 
therapy, a gold-standard HPV test is required for quick, robust, and reliable assessment of 
each tumor biopsy. There are two primary categories of HPV tests that are available for use 
on tumor specimens:  signal hybridization and target amplification assays.  
The signal hybridization group includes 3 methods for detection of HPV DNA 1) In 
situ hybridization (ISH), such as the Inform HPVIII test, which detects 16 hrHPV types with 
pooled DNA probes, 2) the Digene Hybrid Capture 2 test, which employs RNA probes (13 
hrHPV and 5 lrHPV types in separate reactions), followed by labeled antibodies to 
DNA/RNA hybrids, and 3) the Cervista Invader test, which detects 14 hrHPV types through 
adjacent hybridization of probe and invader oligonucleotides (overlapping by one 
nucleotide base), forming a triplex structure. The triplex is enzymatically removed, 
generating a reporter signal in the subsequent reaction.  
Additional signal hybridization tests involve protein detection by 
immunohistochemistry (IHC). Immunohistochemical staining for p16INK4a provides a 
surrogate marker for HPV E7 activity, and IHC for HPV E6 and E7 oncoproteins is also used 
for visualization of oncoprotein expression.   
Application of HPV target amplification tests is broader than that of the 
hybridization tests; the first is consensus PCR of HPV DNA, which theoretically detects any 
HPV types present, using pooled primer sets to amplify HPV DNA.  Consensus primer 
assays include degenerate L1 primers to amplify 450bp amplicons (MY09/MY11), 
overlapping L1 primers to amplify 450bp amplicons (PGMY), a single pair of L1 primers 
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under very low stringency PCR conditions to generate 150bp amplicons (GP5+/6+), L1 
primers to amplify short 65bp amplicons (SPF10), and the RealTime HR HPV assay, which 
uses real-time PCR for HPV16- and HPV18-specific detection and pooled detection for 
other hrHPV types.   
The Aptima HPV test uses consensus reverse-transcription PCR of RNA to detect E6-
E7 transcripts of 14 hrHPV types. The other HPV RNA detection assay is the HPV Proofer 
test, which combines RNA Nucleic Acid Sequence Based Amplification (NASBA) with type-
specific molecular beacons for 5 hrHPV types.   
HPV genotyping commonly combines target amplification with signal hybridization. 
Midrange genotyping is achieved with the BD Viper Assay, using multiplex real-time PCR to 
detect HPV (consensus primers) plus individual typing 6 hrHPVs.  Consensus PCR is 
routinely the first step in full genotyping methods. GP5+/6+-PCR-EIA amplifies a region of 
L1 with GP5+/6+ consensus primers and identifies specific HPV types by probe 
hybridization and enzyme immunoassay. Consensus PCR followed by hybridization of 
amplicons to type-specific probes immobilized to nylon strips is the method employed by 
the Linear Array (PGMY consensus primers) and InnoLiPA (SPF10 consensus primers) 
tests.   
HPV genotyping can also be performed by microarray methods. The Papillocheck 
HPV test combines PCR amplification of the E1 region with hybridization to 24 lrHPV and 
hrHPV type-specific probes on a low-density microarray, which generates a fluorescent 
signal for any of the types present in the sample.  Similarly, the CLART HPV2 test amplifies 
and biotinylates a portion of the L1 region, followed by hybridization to type-specific 
probes in a low-density microarray; an enzymatic color reaction indicates the presence of 
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up to 35 HPV types. The high-risk HPV multiplex PCR-MassArray method that is used in our 
group detects and identifies 16 hrHPV and 2 lrHPV subtypes using type-specific, multiplex, 
competitive PCR and single base extension followed by MALDI-TOF (Matrix-Assisted, Laser 
Desorption/Ionization- Time of Flight)  Mass Spectrometry analysis.  Finally, the 
Multimetrix HPV genotyping test uses Luminex technology for identification of up to 100 
different HPV targets; color-coded microsphere beads are covalently attached to type-
specific HPV probes and are identified by flow cytometry when the target is present. 
There are benefits and challenges associated with each HPV detection method used. 
There is no one best method; determination of the most appropriate test is often 
dependent on sample availability and state (formalin-fixed, paraffin-embedded (FFPE) or 
fresh-frozen). Among signal hybridization methods, none of the assays identify specific 
HPV types in the sample. HPV ISH is optimized for FFPE tissues and provides a visual 
demonstration of viral distribution, but lacks specificity and interpretation may be 
subjective. The Hybrid Capture II and Cervista tests are both solution hybridization assays 
approved for cervical screening, but may not be suitable for tissue analysis. IHC for p16INK4a 
is optimized for FFPE tissues and frequently represents active virus, but has low specificity. 
HPV E6 and E7 IHC allows a visual correlate to viral oncoprotein expression, but 
performance of the current assay is poor.  A common difficulty encountered with target 
amplification methods is the need for tissue processing to obtain the DNA or RNA required 
for the assay. All of the consensus PCR methods have high sensitivity, but are time- and 
labor- intensive and are unable to identify HPV types present. RNA-based target 
amplification methods are informative in that they exclude latent or inactive HPV that 
would be detected by DNA methods, but are severely limited by the requisite fresh-frozen 
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tumor specimen for suitable RNA isolation.  The more complex genotyping methods 
provide the greatest information, and are highly sensitive and specific, but typically require 
expensive specialized instrumentation or assay platforms that may not be available or 
obtainable.  
Oropharynx: The incidence of OPSCC is increasing as smoking-related cancers 
decrease.  The increase is due to hrHPV-induced disease136,137, which has emerged as the 
primary etiologic factor in OPSCC, surpassing tobacco and alcohol in this type of head and 
neck squamous cell carcinoma31,34,36,40,136-140.  The incidence of oropharyngeal cancer is 
predicted to reach 13,000 cases in the US in 2013; 65-85% HPV-positive with expected 3-
year failure rates of 30-36%30.  There is growing controversy over the optimal strategy for 
oropharynx cancer treatment, given the evolving epidemiology.  Early lymph node 
metastasis is common in HPV-driven head and neck cancers and most patients present 
with advanced disease.  Response to therapy and survival is dramatically better in patients 
with HPV-positive tumors than in those with HPV-negative oropharynx cancer30-40.  
Because of this, many clinicians advocate for a reduction in treatment intensity for patients 
with HPV-induced cancers to minimize post-treatment morbidity141,142.  However, a 
reduction in treatment intensity risks the possibility of under-treatment, tumor 
progression, and metastasis in patients who might have been cured with the current 
intensity of treatment. Under current treatment regimens, a subset of 20-30% of patients 
with HPV-induced tumors fail to respond to therapy and develop distant metastasis143; this 
subset would likely increase with a reduction in treatment intensity. 
Nasopharynx: The primary etiologic agent of non-keratinizing type II and III 
nasopharyngeal carcinoma (NPC) is the Epstein-Barr herpesvirus (EBV); however, 
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keratinizing type I NPC is not associated with EBV, indicating an alternate pathogenic 
mechanism144,145.  The thin epithelium in the crypts of the palatine and lingual tonsils in the 
oropharynx is very similar to the epithelium of the adenoidal tonsil in the nasopharynx.  
Both pharyngeal sites contain abundant lymphoid cells and both are part of Waldeyer’s 
ring of lymphocytic tissues.  These tissue similarities have recently prompted interest in 
the possibility of HPV as an alternate etiologic agent of NPC.  Several studies have reported 
HPV-positive NPC, most frequently as HPV-positive/EBV-negative tumors146-151.  A recent 
study at our institution (unpublished data, Stenmark et al., 2013) has demonstrated 
mutually exclusive EBV and HPV in NPC tumors, and that both EBV-positive and HPV-
positive tumors were predominantly non-keratinizing type II and III, while EBV-
negative/HPV-negative tumors were largely keratinizing type I NPC. The results of this 
study also demonstrate that among nasopharynx cancer patients treated at the University 
of Michigan, those with HPV-positive nasopharyngeal tumors had poorer outcome than 
EBV-positive patients (unpublished data, Stenmark et al., 2013). 
Oral cavity: The possible role for hrHPV in the etiology of oral cavity squamous cell 
carcinoma (OCSCC) is currently undefined.  The role of hrHPV in carcinogenesis of the oral 
cavity is further obscured by discordant findings between p16INK4a IHC and HPV testing in 
these tumors. While HPV is detected in relatively few OCSCC tumors, the majority of these 
tumors exhibit overexpression of p16.  It was recently reported that the majority of p16-
positive OCSCC tumors were negative for hrHPV, making p16INK4a IHC an unsuitable 
surrogate for HPV detection152,153.  Reports that patients with OCSCC have poorer outcome 
than patients with HNSCC at other sites, regardless of HPV status152, suggest that HPV may 
not be a primary carcinogenic driver in these tumors. 
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Larynx: Tobacco and alcohol remain the primary etiologic agents in laryngeal 
carcinogenesis154. While hrHPV has been detected in a subset of larynx cancers, it has also 
been reported to be present in benign and normal larynx tissue, likely representing latent 
infections155.  A recent study by Halec et al. assessed laryngeal carcinoma specimens for 
active HPV involvement, examining hrHPV DNA, HPV E6*I transcripts, and p16 
expression154.  They found that 32 of 92 (35%) samples were positive for HPV16 DNA, 6 of 
30 (20%) samples had HPV16 E6*I transcripts, and p16 expression was seen in 4/75 (5%) 
of cases, with correlation between analyses. The authors conclude that the agreement 
between HPV16 DNA, HPV16 E6*I transcripts and p16 expression provides evidence for a 
causal role of HPV16 in this subset of laryngeal tumors154.  Involvement of HPV in laryngeal 
carcinogenesis is further supported by detection of integrated hrHPV in laryngeal 
tumors156.  
 
Data Chapter Overview  
In this dissertation, we examined high-risk human papillomavirus-driven 
carcinogenesis in HNSCC. In Chapter II we present evidence that the HPV PCR-MassArray 
assay, together with p16INK4a immunohistochemical staining, is the optimal assessment for 
HPV detection, typing, and viral oncogene activity in formalin-fixed, paraffin-embedded 
HNSCC tissue biopsies.  In chapter III, we evaluated seven HPV16-positive HNSCC cell lines.  
Each cell line expressed HPV E6 and E7 oncogenes and demonstrated alternate splicing, 
indicating active viral oncogenesis. Additionally, each cell line exhibited viral integration 
into known cellular genes, including cancer related genes TP63, DCC, JAK1, TERT, ATR, 
ETV6, PGR, PTPRN2, and TMEM237.  This assessment was extended into HNSCC tumors in 
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chapter IV, where we examined HPV oncogene expression and viral integration in five 
tumors that were responsive to treatment and five that did not respond to treatment and 
recurred. All of the tumors demonstrated active viral oncogenesis, indicated by expression 
of HPV E6 and E7 oncogenes and alternate E6 splicing.  In the responsive tumors, HPV 
integration was found in numerous extragenic chromosome regions, as well as one 
integration event into a known cancer-related gene, TP63. In the recurrent tumors, two 
HPV integration events were found in extragenic regions on chromosome 10, and each 
recurrent tumor exhibited HPV integration into known cellular genes, including cancer-
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High-risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and 
Oral Cavity Cancers: Comparison of Multiple Methods 
 
Abstract 
Human papillomaviruses are now recognized as an etiologic factor in a growing 
subset of head and neck cancers and have critical prognostic importance that affects 
therapeutic decision making.  There is no universally accepted gold standard for high-risk 
HPV (hrHPV) assessment in formalin-fixed, paraffin-embedded (FFPE) tissue specimens, 
nor is there a clear understanding of the frequency or role of hrHPV in sites other than 
oropharynx.   
The objective of this study was to determine the optimal assessment of hrHPV in 
FFPE head and neck tumors.  We tested 338 FFPE head and neck squamous cell carcinoma 
(HNSCC) specimens from the oropharynx (OPSCC), nasopharynx (NPC), and oral cavity 
(OCSCC) for hrHPV, using p16INK4a immunohistochemical (IHC) staining, HPV in situ 
hybridization (ISH), and PCR-MassArray (PCR-MA). We used PCR with HPV L1 PGMY 
consensus primers (L1 PGMY-PCR) and sequencing to resolve method discordance. 
Relative sensitivity and specificity were compared to develop a standard optimal test 
protocol.   
Using combined PCR-MA with L1 PGMY-PCR and sequencing for conclusive results, 
we found PCR-MA to have 99.5% sensitivity and 100% specificity, p16 IHC to have 94.2%       
sensitivity and 85.5% specificity, and ISH to have 82.9% sensitivity and 81% specificity.  
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Among HPV-positive tumors, HPV16 was most frequently detected, but 10 non-HPV16 
types accounted for 6-50% of tumors, depending on site.  Overall, 86% of oropharynx, 50% 
of nasopharynx and 26% of oral cavity tumors were positive for hrHPV.  
This work demonstrates highlights the advantages of the HPV PCR-MA assay, 
including low DNA (5ng) requirement, efficacy for small tissue sample testing, high 
throughput, and rapid identification of HPV types. The PCR-MA assay also has the highest 
sensitivity and specificity of the methods tested. PCR-MA together with p16INK4a provided 
accurate assessment of HPV presence, type, and activity, and was determined to be the best 
approach for HPV testing in FFPE head and neck tumors.  
 
Introduction 
The role of carcinogenic hrHPV in the etiology of head and neck cancer has been 
increasing in significance over the past 20 years1-5.  In our institution, 80 to 90 percent of 
oropharyngeal cancers are HPV-positive6, and evidence for hrHPV in head and neck 
squamous cell carcinoma (HNSCC) of other sites is also increasing5,7-9.  Generally, HPV-
positive oropharyngeal cancers exhibit better responses to treatment than do HPV-
negative tumors6,10-18.  A recent trial conducted in our institution using concurrent 
platinum-taxol based chemotherapy and intensity modulated radiation therapy resulted in 
88% three year progression-free survival among oropharynx cancer patients with stage 3 
and 4 disease19.  However, a recent report from Belgium reported that survival among 
HPV-positive patients with oral cavity cancer was worse than their HPV-negative 
counterparts9.  Similarly, among nasopharynx cancer patients treated at our institution, 
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those with HPV-positive nasopharyngeal tumors had poorer outcome than those with EBV-
positive tumors (unpublished data, Stenmark et al., 2013).   
Many reports indicate that HPV-positive tumors with transcriptionally-active viral 
oncogenes are those most likely to respond well to treatment20-22.  In contrast to low-risk 
HPV types such as HPV6 and HPV11 which also infect mucosal epithelia but rarely cause 
cancer, the high risk HPV types HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 
have all been implicated in oncogenesis23-27. This difference between low and high-risk 
HPV types is due in part to the nature of the E6 and E7 viral oncogenes that exhibit 
alternate splicing in high-risk HPV, resulting in transforming capacity.  Thus, for precision 
medicine28 it is important to assess not only the presence of HPV16 but also other hrHPV 
types.  This will be essential to accurately determine the most effective treatment option 
for each patient based on their individual tumor characteristics. Optimally, viral oncogene 
activity is determined using high quality tumor RNA20,21 to identify alternate transcripts 
linked to transformation20 or assessing HPV E6 and E7 indirectly by detection of patient 
antibodies to E6 and E722. However, availability of fresh frozen tumor tissue or access to 
serologic assays is rare, whereas fixed tumor from the diagnostic biopsy is more readily 
accessible.  Therefore, it is essential to have robust and accurate testing methods using 
FFPE materials to complement the histopathologic and clinical staging data to arrive at the 
optimal therapeutic plan. 
Multiple methods of HPV detection and assessment are widely used but the optimal 
testing method has yet to be clearly defined.  Immunohistochemical detection of highly 
expressed p16INK4a is a widely used surrogate method for the presence of HPV in a tumor.  
This biomarker is indicative of hrHPV E7 oncogene expression, which upregulates p16 
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through disruption of the Rb/E2F transcription factor complex.  However, p16 can be 
upregulated by mechanisms other than HPV, leading to false positive assessment of HPV in 
the sample9,29,30.  In head and neck cancers, p16 is also one of the most frequently lost 
genes, and as such could provide a false negative evaluation of the presence of HPV31-36.  
Direct detection of HPV DNA in tumor cells by ISH is also widely used in pathology 
departments, and has the advantage of identifying the presence and location of the viral 
DNA within tumor cells, but this method lacks sensitivity37.  Polymerase chain reaction 
(PCR) based methods are highly advantageous because they require little DNA, but these 
often lack the ability to detect multiple high-risk types or to identify the high-risk type 
present, a shortcoming shared by both p16 assessment and in situ hybridization.  Several 
years ago, Yang et al. 38 developed a multiplex HPV PCR-MA assay that allows highly 
sensitive detection of multiple HPV types and allows specific HPV type identification in a 
single assay.  We have used this assay extensively in our studies on hrHPV in head and neck 
cancers6,7,11,12,14.   
Because many HPV-positive tumors respond well to therapy, there are national and 
local efforts to significantly decrease treatment intensity for patients with these tumors to 
spare them from unnecessary treatment morbidity.  However, even with very aggressive 
concurrent chemoradiation therapy, a subset of 20-30% of patients with HPV-positive 
oropharyngeal cancer progress either locally or with distant metastases.  It has been 
suggested that the HPV-positive tumors that are driven primarily by the HPV viral 
oncogenes are the most likely to have a good response to treatment.   Thus, there is a 
growing need for reliable and rapid tests for detection of transcriptionally active HPV in 
head and neck cancers to select patients for the most appropriate treatment based on their 
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own tumor characteristics.  In this study we compared three commonly used HPV 
assessment tools: HPV PCR-MassArray for 15 high-risk HPV types, HPV in situ 
hybridization for 12 high-risk types, and p16 IHC staining.  We then used consensus L1 
PGMY-PCR39,40 and sequencing to resolve discordant results for tumors that were HPV-
negative by PCR-MassArray but p16-positive or ISH-positive.  From our results we propose 
an optimal HPV detection/identification algorithm. 
 
Methods 
Patient specimens:  All patients provided written informed consent to study their 
tissue under a study approved by the Institutional Review Board for the medical school.  
Tumor specimens from 338 advanced stage head and neck cancer patients enrolled in the 
Head and Neck SPORE were obtained and evaluated, including 212 oropharyngeal, 18 
nasopharyngeal, and 108 oral cavity cancers. FFPE tumor cores from pretreatment biopsies 
and/or post-treatment recurrences (when available) were used to construct tissue 
microarrays for in situ hybridization and immunohistochemical staining.  FFPE tumor 
cores were also taken from each tumor block at the time of array construction for genomic 
DNA extraction. 
p16INK4a immunohistochemical staining:  Assessment of p16INK4a was performed 
per supplier protocol (CINtec p16INK4a Histology Kit; mtm Laboratories).  Antibody binding 
was scored by an experienced head and neck pathologist (J.B.M.), using a continuous scale 
for the proportion of tumor cells demonstrating nuclear and cytoplasmic p16 staining. 
Percentage scored was divided into a quartile scale of 1 to 4 (1 was less than 5%; 2, 5%-
20%; 3, 21%-50%; and 4, 51%-100% tumor staining). Intensity was also scored on a scale 
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of 1 to 4 (1 equal to no staining; 2, low intensity; 3, moderate; and 4, high intensity). 
Staining for p16 was considered positive when the proportion score was equal to 4 and the 
intensity score was 3 or 4. Examples of p16INK4a staining are shown in Figure II.A, II.C, and 
II.E. 
HPV in situ hybridization (ISH): HPV in situ hybridization was performed per 
supplier protocol (INFORM HPVIII ISH assay; Ventana) in our pathology laboratory and 
scored by a pathologist (J.B.M.). The assay includes probes for 12 hrHPV types: HPV16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58 and 66. Examples of HPV ISH are shown in Figure II.B, II.D, 
and II.F. 
HPV PCR-MassArray (PCR-MA): Genomic DNA was extracted from FFPE tumor 
cores using the DNeasy Blood and Tissue Kit (Qiagen). Samples were assayed in 
quadruplicate using a validated, ultra-sensitive method of real-time competitive 
polymerase chain reaction, followed by probe-specific single base extension. Multiplex PCR 
amplification of the E6 region of 15 discrete high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66, 68 and 73), as well as a human glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) control were processed to saturation, followed by a shrimp 
alkaline phosphatase quenching. Amplification reactions included synthetic competitor 
oligonucleotides identical to each natural amplicon except for a single nucleotide 
difference.  Multiplex single base extension reactions used probes to identify unique 
sequences in the amplified E6 region of each hrHPV type.  Single terminal base extension 
was designed to create a 40 to 80 Da difference in mass between each competitor and wild 
type extension product. These were then analyzed by mass separation in assay-defined 
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Figure II.1.  PCR-MassArray Detection of hrHPV. Expanded mass spectrum region from 5900 































profiles by matrix-assisted laser desorption/ionization time-of flight (MALDI-TOF) mass 
spectrometer6,7,11,12,14 (Figure II.1).  
HPV L1 PGMY-PCR and sequencing: Consensus PCR using L1 PGMY09/PGMY11 
primers was carried out on tumor DNA from p16-positive or ISH-positive cases that were 
negative by HPV PCR-MassArray.  The conditions of PCR were as previously described39,40.  
Amplicon products from L1 PGMY-PCR-positive cases were submitted for Sanger 




A.   HPV Type p16-POS 
  N (%) N (%) 
OROPHARYNX*  HPV16** 162 (93.6) 151 (96.8) 
PCR-MassArray p16 ISH  HPV16, 35, 66 1 (0.6) 1 (100) 
 POS 173 83% POS 170 83% POS 120 73%  HPV16, 33 1 (0.6) 1 (100) 
 NEG 35 17% NEG 35 17% NEG 44 27%  HPV18 2 (1.2) 2 (100) 
total 208  total 205  total 164   HPV33 3 (1.7) 3 (100) 
* Of 212 oropharynx cancers, 183 were positive by at least one test.  HPV35 3 (1.7) 3 (100) 
** 6 HPV16-positive oropharynx tumors lacked p16 data  HPV39 1 (0.6) 0 
  total 173 161 (96.4) 
           
           
B.   HPV Type p16-POS 
   N (%) N (%) 
NASOPHARYNX*  HPV16 3 (37.5) 3 (100) 
PCR-MassArray p16 ISH  HPV18 2 (25.0) 2 (100) 
 POS 8 44% POS 9 50% POS 0 0%  HPV39 1 (12.5) 1 (100) 
 NEG 10 56% NEG 9 50% NEG 1 100%  HPV59 2 (25.0) 2 (100) 
 total 18  total 18  total 1   total 8 8 (100) 
   * Of 18 nasopharynx cancers, 9 were positive by at least one test.     
     
     
C.   HPV Type p16-POS 
   N (%) N (%) 
ORAL CAVITY*  HPV16 4 (40.0) 3 (75.0) 
PCR-MassArray p16  ISH  HPV16, 35 1 (10.0) 0 
 POS 10 10% POS 20 19% POS 5 26%  HPV31 1 (10.0) 1 (100) 
 NEG 94 90% NEG 86 81% NEG 14 74%  HPV33 1 (10.0) 1 (100) 
 total 104  total 106  total 19   HPV35 1 (10.0) 0 
   * Of 108 oral cavity cancers, 28 were positive by at least one test.  HPV39, 58 1 (10.0) 0 
          HPV66 1 (10.0) 0 
          total 10 5 (50.0) 
          
Table II.1. HPV Detection Test Results by Tumor Site and Method. PCR-MassArray hrHPV 
type determination, and p16 status. POS- positive, NEG- negative 
 
Results 
The 338 tumors were tested and compared by at least 2 of the 3 methods as 
summarized by tumor site in Table II.1.  As expected, the most frequently HPV-positive 
tumors were from oropharynx; with 173/208 (83%) positive by PCR-MA, 170/205 (83%) 
positive by p16, and 120/164 (73%) positive by ISH.  Taken together, 183/212 (86%) of 
the oropharynx tumors were HPV-positive by one or more method, and 29/212 (14%) of 
the oropharynx tumors were HPV-negative by all tests performed on those samples 
(minimum of two tests each).  The predominant HPV type determined by PCR-MA in   
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Figure II.2. Representative p16INK4a Immunohistochemistry and HPV In Situ 
Hybridization in Oropharyngeal Tumors. Panels A, C and D show p16 and panels B, D 
and F show ISH. Panels A and B show p16 and ISH (respectively) in a tumor with 1.5 
copies HPV/cell; Panels C and D show p16 and ISH (respectively) in a tumor with less 
than 1 copy HPV/cell; and Panels E and F show p16 and ISH (respectively) in a tumor 





oropharynx was HPV16 alone (162/173, 94%).  However, six percent of oropharynx 
tumors contained other high-risk types including: HPV18 (2), HPV33 (3), HPV35 (3), 
HPV39 (1), and 2 cases that contained multiple HPV types, one positive for HPV16, 35 and 
66, and one positive for HPV16 and 33 (Table II.1A).  The mass spectrum for the 
oropharyngeal tumor that contains both HPV16 and HPV 33 is illustrated in Figure II.1, and 
Figure II.2 shows representative p16 and HPV ISH results for 3 HPV-positive oropharynx 
tumors.   
Of the 18 nasopharynx tumors, 9/18 (50%) were p16-positive and 8/18 (44%) 
were PCR-MA-positive, only 1/18 was tested by ISH and it was negative by ISH, but positive 
by both other assays. The hrHPV types identified in the 8 PCR-MA-positive nasopharynx 
tumors were more heterogeneous than in the oropharynx tumors with HPV16 (3), HPV18 
(2), HPV39 (1) and HPV59 (2) (Table II.1B).  The oral cavity tumors were less frequently 
HPV-positive, with only 28/108 (26%) tumors HPV-positive by one or more methods, and 
80 (74%) tumors HPV-negative by all tests (minimum of two tests). The hrHPV types 
identified in the oral cavity tumors were HPV16 (4), HPV31 (1), HPV33 (1), HPV35 (1), 
HPV66 (1), and two cases with multiple infections, one containing HPV16 and 35, and one 
with HPV39 and 58 (Table II.1C). Of the 330 tumors from all sites tested by HPV PCR-
MassArray, 191 (58%) were HPV-positive and 140 (42%) were HPV-negative.  Of the 329 
tumors tested by p16 staining, 199 (60%) were p16-positive and 130 (40%) were p16-
negative. Of the 184 tumors tested by HPV in situ hybridization, 125 (68%) were HPV-
positive and 59 (32%) were HPV-negative (Table II.2).    
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PCR-MA: 330 Tumors  PCR-MA Positive 191/330 (58%)  
Concordant Positive-              
All Methods 
POS by PCR-MA, p16 and ISH  105 
POS by PCR-MA and p16  49 
POS by PCR-MA and ISH 5 
PCR-MA Positive, 
Discordant Other 
POS by p16, NEG by ISH, POS by PCR-MA 20 
NEG by p16, NEG by ISH, POS by PCR-MA 3 
NEG by p16, POS by ISH, POS by PCR-MA 2 
NEG by p16, POS by PCR-MA 6 
NEG by ISH, POS by PCR-MA 1 
     
p16:  329 Tumors p16 Positive 199/329 (60%) 
Concordant Positive-             
All Methods 
POS by p16, PCR-MA and ISH  105 
POS by p16 and PCR-MA 49 
POS by p16 and ISH 3 
p16 Positive,             
Discordant Other 
POS by ISH, NEG by PCR-MA, POS by p16 5 
NEG by ISH, NEG by PCR-MA, POS by p16 3 
NEG by ISH, POS by PCR-MA, POS by p16 20 
NEG by PCR-MA, POS by p16 13 
NEG by ISH, POS by p16 1 
     
ISH: 184 Tumors ISH Positive 125/184 (68%) 
Concordant Positive-             
All Methods 
POS by ISH, p16 and PCR-MA 105 
POS by ISH and p16 3 
POS by ISH and PCR-MA 5 
ISH Positive,               
Discordant Other 
POS by p16, NEG by PCR-MA, POS by ISH 5 
NEG by PCR-MA, NEG by p16, POS by ISH 1 
NEG by p16, POS by PCR-MA, POS by ISH 2 
NEG by PCR-MA, POS by ISH 3 
NEG by p16, POS by ISH 1 
     
L1 PGMY-PCR: 25 Tumors  PCR-MA Negative, L1 PGMY-PCR Positive 1/25 (4%) 
PCR-MA Negative, 
Discordant Other 
POS by p16, NEG by ISH, NEG by PCR-MA 0/3 
POS by p16, POS by ISH, NEG by PCR-MA 1/5 
NEG by p16, POS by ISH, NEG by PCR-MA 0/1 
POS by p16, NEG by PCR-MA 0/13 
POS by ISH, NEG by PCR-MA 0/3 






Figure II.3. Assay Agreement Between Detection Methods 
Tested.  Panel A: Assay agreement among 167 samples tested with 
all 3 methods. Panel B: Assay agreement among 171 samples tested 
with 2/3 methods. Circled numbers represent samples retested by 
L1 HPV consensus PGMY-PCR.  
 
There were 167/338 tumor specimens tested by all three methods, 105 were HPV-positive 
by all methods, 28 were negative by all methods, and 34 samples were discordant by at 
least one method (Figure II.3, Panel A and Table II.2). The remaining 171/338 samples 
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were tested by only 2 of the 3 methods. Of these, 57 (49 by PCR-MA and p16, 5 by ISH and 
PCR-MA, and 3 by p16 and ISH) were HPV-positive by the 2 methods used, 89 were HPV 
negative by the 2 methods used, and 25 samples were discordant (Figure II.3, Panel B and 
Table II.2).  All 25 tumors that were HPV-negative by HPV PCR-MA but p16-positive or ISH-
positive (9 cases shown circled in Figure II.3, Panel A and 16 cases shown circled in Figure 
II.3, Panel B) were further analyzed by consensus PCR using optimized L1 
PGMY09/PGMY11 primers39,40.  Of these, all 17 of the oral cavity tumors that were negative 
PCR-MassArray but p16-positive or ISH-positive remained HPV-negative when tested with 
L1 PGMY-PCR.  Of the 7 oropharynx cancers that were negative by HPV PCR-MassArray but 
p16-positive or ISH-positive, 1 was found to contain HPV DNA using L1 PGMY-PCR.  That 
tumor was p16-positive and ISH-positive, and was found to harbor HPV16 as determined 
by Sanger sequencing of the L1 PGMY-PCR product. The single nasopharynx cancer that 
was p16-positive but HPV-negative by PCR-MassArray was also HPV-negative by HPV L1 
PGMY-PCR.  Of note, all of the EBV-positive nasopharynx tumors were HPV-negative and 
p16-negative.  Across the three sites, 169 tumors contained only HPV16, of these 163 had 
p16 data: 157 (96%) were p16-positive and 6 (4%) were p16-negative.  Twenty-two 
tumors contained other high risk HPV types, three in combination with HPV16.  Of these, 5 
of the 22 (23%) failed to express p16: one tumor with HPV16 and HPV35, one with HPV35, 




  HPV PCR-MA       
  
 
PCR/SEQ + PCR/SEQ - 
 
  
  PCR-MA+ 191 (TP) 0 (FP) 191   
  PCR-MA- 1 (FN) 138 (TN) 139   
  
 
192 138 330   
       Sensitivity= TP/(TP+FN)= 191/192= 99.5%   
  Specificity= TN/(FP+TN)= 138/138= 100%   
      
  p16 IHC       
  
 
PCR/SEQ + PCR/SEQ - 
 
  
  p16+ 178 (TP) 20 (FP) 198   
  p16- 11 (FN) 118 (TN) 129   
  
 
189 138 327   
       Sensitivity= TP/(TP+FN)= 178/189= 94.2%   
  Specificity= TN/(FP+TN)= 118/138= 85.5%   
      
  HPV ISH        
  
 
PCR/SEQ + PCR/SEQ - 
 
  
  In Situ+ 116 (TP) 8 (FP) 124   
  In Situ- 24 (FN) 34 (TN) 58   
  
 
140 42 182   
       Sensitivity= TP/(TP+FN)= 116/140= 82.9%   
  Specificity= TN/(FP+TN)= 34/42= 81%   
Table II.3. Assay Performance Using PCR-MA/L1 PGMY- PCR and 
Sequencing (PCR/SEQ) as the Definitive Testing Assay. 
When evaluating the performance of the assays using combined PCR-MA with L1 
PGMY-PCR and sequencing as the definitive assay, the HPV PCR-MassArray had a 
sensitivity of 99.5% and a specificity of 100%, p16 assay had a sensitivity of 94.2% and a 
specificity of 85.5%, and the in situ hybridization assay had lower sensitivity of 82.9% and 






The association of high-risk HPV with oropharynx cancer is now well 
established1,3,6,10-12,14,20,41-43.  Recently, hrHPV has also been implicated in a subset of 
nasopharyngeal carcinomas in white North Americans 7,44-47, and in other head and neck 
cancer sites, including oral cavity cancers48,49 The goal of this study was to carefully assess 
a large number of head and neck squamous cancers from three different sites (oropharynx, 
oral cavity and nasopharynx) using p16INK4a staining, HPV in situ hybridization, and HPV 
PCR-MassArray on the same samples, to determine the true incidence of high-risk HPV 
involvement in the tumors, and to assess the relative sensitivity and specificity of each 
detection method.  This study revealed that among these tumor sites at a large Midwestern 
referral center, more than 80% of oropharynx cancers, approximately half of 
nasopharyngeal cancers, and 10% of oral cavity cancers contain high-risk HPV.   
In the oropharynx, 95% of the HPV-positive tumors contained HPV16, including 2 
tumors that also contained one or two additional high-risk HPV types.  Five percent of the 
HPV-positive oropharynx cancers contained other high-risk types (HPV18, HPV33, HPV35, 
and HPV39).  However, in nasopharynx and oral cavity, more than half of the HPV-positive 
tumors contained non-HPV16 high-risk types.  The presence of both HPV16 and other high 
risk HPV types in the absence of EBV in NPC is a strong indictment of HPV as a causal factor 
in a subset of nasopharynx cancers.  This is reinforced by the strong concordance of p16 
positivity with HPV and with the observation that neither EBV-positive nor HPV and EBV 
double negative tumors express p16.    
In oropharynx cancer, HPV-positive tumors have a more favorable outcome than 
HPV-negative tumors.  However, little is known about the effect of HPV on outcome in 
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other sites in the head and neck.  Studies from Belgium have reported both a high incidence 
(44%) of hrHPV-positive oral cancers and a very poor prognosis for these tumors when 
compared with the HPV-negative oral cavity tumors49.  Similar results were reported from 
Taiwan48.  We found a much lower proportion of high-risk HPV-positive oral cavity tumors 
(10%) and among these we observed a higher rate of HPV heterogeneity with 40% 
containing only HPV16 and 60% that had other hrHPV types.  Our proportion of HPV-
positive oral cavity cases is relatively small, and whether these represent a separate 
prognostic group in oral cavity cancer is unknown.  We also found a higher rate of HPV type 
heterogeneity in nasopharynx cases with 38% HPV16 and 62% other high-risk types.  We 
have recently completed a survey of a much larger set of nasopharyngeal cancer cases that 
confirms the HPV type heterogeneity as well as demonstrates that HPV-positive 
nasopharyngeal cancer has a poorer prognosis than EBV-positive/HPV-negative 
nasopharyngeal cancer (unpublished data, Stemark et al., 2013).   
While HPV16 is the most common cause of cervical cancer, only 59% of cervical 
cancers are driven by only HPV16; the remaining 41% contain other hrHPV types23,50.  
These types other than HPV16 constitute a significant subset of cancers in the oropharynx 
and other sites, and exhibit evidence that the virus is driving the cancer by high levels of 
p16 expression. Therefore, these tumors cannot be excluded from consideration.  
Furthermore, a significant subset of p16 and HPV-positive oropharynx tumors (20-30%) 
recur or progress with distant metastatic spread, yet the reason for this is unknown.  It may 
be that non-HPV16 types are responsible for the outlier tumors, or perhaps these tumors 
driven by other hrHPV types are responding well to therapy.  We already know that many 
of the recurrent and/or metastatic cancers in our set contain HPV16, suggesting that 
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tumors driven by non HPV16 types are as likely to respond to current therapies as the 
HPV16-driven tumors. Accordingly, it is important to include the other types, and to carry 
out larger studies to determine if tumors driven by non-HPV16 types can be assigned to 
reduced intensity treatments.   
In this study, p16 expression status was determined in the majority of tumors 
evaluated, and there was a significant correlation between p16-positive and HPV-positive 
results (correlation coefficient= 0.999, p<0.001). This indicates that the virus is 
transcriptionally active in nearly all HPV-containing tumors, suggesting that it is unlikely 
that the HPV is strictly an incidental passenger.  Nevertheless, of 186 tumors for which an 
HPV type was identified and p16 staining was carried out, 175 (94%) were p16-positive 
and 11 (6%) were p16-negative.  Whether this represents a subset of 6% in which HPV is 
not a driving mechanism or whether this subset has incurred a mutation, deletion or 
methylation event affecting CDKN2A is a subject for further investigation.   
Many groups have surveyed oropharyngeal tumors for HPV, and some have 
examined multiple head and neck tumor sites43, and have used a variety of detection 
methods51.  The present study represents one of the largest series of head and neck tumors 
from different sites evaluated by multiple assay methods for the presence of hrHPV.  The 
PCR-MassArray assay has features that make it the optimal test in our hands.  The 
minimum requirement for input DNA is very low; 5ng is adequate for evaluation.  The assay 
has high sensitivity and specificity, and identifies each hrHPV type using specific primers, 
probes and competitors, and it focuses on the E6 region to confirm that this transforming 
oncogene is present in the sample.  Evaluation of the cyclin-dependent kinase inhibitor 
protein, p16INK4a, is a valuable diagnostic addition to the PCR-MA assay, because it typically 
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represents the transcriptional activity of the E7 oncogene.  In our series, there was one 
oropharynx tumor that was negative by HPV PCR-MassArray but p16-positive and ISH-
positive that was later confirmed to contain HPV16 by L1 PGMY-PCR and sequencing.  We 
speculate that the PCR-MA assay missed this single case owing to rearrangement of the 
viral genome that affected part of the E6 oncogene.  More commonly, p16 is overexpressed 
in a subset of tumors in the absence of hrHPV.  Other mechanisms of p16 overexpression 
include mutation of Rb, amplification of cyclinD1, and overexpression of E2F family 
members.  In this series of tumors, reanalysis of discordant cases revealed that 24/25 
tumors that were negative by HPV PCR-MassArray but p16-positive remained HPV-
negative by consensus L1 PGMY-PCR.  
In situ hybridization for hrHPV has high specificity among known HPV-positive 
tumors, but has comparatively low sensitivity and can miss HPV-containing tumors as 
assessed by other methods. Reanalysis of ISH/PCR-MA discordant cases revealed that all 4 
tumors that were negative by HPV PCR-MassArray but ISH-positive remained HPV-
negative by consensus L1 PGMY-PCR.   
Our findings support the use of a combination of p16 immunohistochemical staining 
and HPV PCR-Mass Array analysis as the optimal assessment for HPV detection, typing, and 
viral oncogene activity in formalin-fixed, paraffin-embedded tissue biopsies.  For 
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Integration of High-Risk Human Papillomavirus into Cellular Cancer-Related Genes in 
Head and Neck Cancer Cell Lines 
 
Abstract 
High-risk HPV-driven carcinogenesis has become the predominant etiologic factor 
in oropharyngeal cancer. Most HPV-positive oropharynx tumors respond well to therapy, 
prompting interest in establishing reduced-intensity treatment protocols, but 
approximately 20% of these tumors fail to respond to therapy or recur within 5 years for 
yet unknown reasons.  This study evaluates viral oncogene expression, copy number, and 
integration sites in HPV-positive head and neck squamous cell carcinoma cell lines from 
patients who progressed.  
Viral oncogene alternate transcripts and copy number were assessed.  Detection of 
integrated papillomavirus sequences-PCR (DIPS-PCR) and sequencing was used to identify 
insertion sites and the host genes affected by viral integration.  RNA expression analysis 
across viral integration sites within cellular genes was also assessed. 
Seven HPV16-positive HNSCC cell lines were evaluated.  All expressed HPV E6 and 
E7 oncogenes and exhibited alternate splicing, indicating active viral oncogenesis.  In 
addition, HPV integration was found within known cellular genes, including cancer related 




The HPV-positive cells lines represent virally-induced tumors that failed to respond 
to therapy and likely represent the non-responsive outlier tumors that must be identified 
before development of reduced-intensity clinical trials.  These results strongly implicate 
viral integration into known cancer related genes as a secondary carcinogenic driver that 
may distinguish non-responsive cancers that will require increased or alternate treatment.  
 
Introduction 
High-risk human papillomaviruses are frequently identified as etiologic factors in 
the increasing incidence of head and neck cancer, particularly hrHPV-positive oropharynx 
cancers.   In contrast, rates of HPV-negative oropharyngeal tumors, which are more often 
smoking and alcohol related, are declining in frequency.  Among patients studied at the 
University of Michigan, over 80% of oropharyngeal cancers, 33% of nasopharynx cancers, 
14% of larynx cancers and 10% of oral cavity cancers are positive for hrHPV1.  In the 
oropharynx, hrHPV is generally considered to be associated with better prognosis2-11.  
Clinical trial data from the University of Michigan shows that patients with stage 3 
and 4 oropharynx cancer had 88% three year progression-free survival after treatment 
with concurrent platinum-taxol based chemotherapy and intensity modulated radiation 
therapy (chemo-RT)12. However, HPV involvement at other head and neck sites is not as 
predictive of better response.  In fact, others have suggested that patients with HPV-
positive oral cavity tumors have worse outcomes than those with HPV-negative tumors13, 
and our work has similarly demonstrated that patients with HPV-positive/EBV-negative 
nasopharynx tumors have poorer outcome than those with HPV-negative/EBV-positive 




subset of HPV-positive oropharynx tumors fails to respond to highly intensive concurrent 
therapies.   
There are relatively few cell lines established from HPV-positive head and neck 
tumors.  We have collaborated with our colleagues around the world to collect and study 
the HPV copy number, oncogene transcription, physical status, integration sites, and 
identification of the cellular genes affected by integration, of all seven HPV16-positive 
HNSCC cell lines available (UD-SCC-2, UM-SCC-47, UM-SCC-104, UPCI:SCC90, UPCI:SCC152, 
UPCI:SCC154, and VU-SCC-147).  All of these cell lines are derived from tumors that failed 
to respond to therapy.  Our findings indicate that these tumors have transcriptionally 
active HPV as demonstrated by strong expression of E6 and E7 oncogenes, including 
expression of the E6 alternate transcripts (E6*I and E6*II) associated with viral 
oncogenesis.  Also, each cell line demonstrated viral integration into genes known to be 
associated with cancer development.  As the overwhelming majority of cervical clinical 
tumor specimens that have been reported in the literature exhibit integration into either 
intragenic regions of the cellular genome or integration into fragile sites14,15, we postulate 
that integration into important cellular genes may be a secondary driver of more highly 
malignant HPV-positive head and neck tumors.   If so, this could provide a way to 
distinguish those HPV-positive tumors unlikely to respond to conventional therapies. 
 
Methods 
Cell lines:  Seven HPV16-positive HNSCC tumor cell lines were studied. Two were 
developed in our lab: UM-SCC-4716,17, and UM-SCC-10416.  UD-SCC-218, was obtained from 




147T)19, from R. Brakenhoff, Vrije Universiteit, Amsterdam; and UPCI:SCC90, UPCI:SCC152, 
and UPCI:SCC154, from S. Gollin and R. Ferris, University of Pittsburgh Cancer Institute20-22 
(Table III.1).  The external cell lines were obtained directly from the originators in 2010.  
All lines were genotyped in the University of Michigan Genomics Core using ProfilerPlus, 
which interrogates 10 tetranucleotide short tandem repeats (STR), and were confirmed to 
have unique genotypes.  UPCI:SCC90 and UPCI:SCC152 share the same genotype, as they 
are derived from separate tumors in the same patient.  All lines were tested upon receipt 
from the donors and repeat confirmatory tests were performed immediately prior to the 
integration experiments carried out between 2012 and 2013. Genomic DNA was extracted 
from cells using the DNeasy Spin Column kit (Qiagen). RNA was isolated from cells using 
the RNeasy Mini Kit (Qiagen), followed by on-column DNase treatment.  
HPV detection, identification, and copy number analysis:  All cell lines were 
grown on glass slides and examined for HPV in situ hybridization (ISH) using the Ventana 
INFORM HPVIII assay (detects 12 hrHPV types: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 
and 66) per supplier protocol. Single color fluorescence in situ hybridization (FISH) was 
performed on UM-SCC-47 using a fluorescein labeled HPV16 bacterial artificial 
chromosome. Metaphase spreads were harvested from UM-SCC-47 cells in their 34th to 36th 
passages using trypsinization and 0.075M potassium chloride hypotonic solution.  Spectral 
karyotyping was performed at the Van Andel Institute.  All cell lines were tested for the 
presence and type of HPV using the HPV PCR-MassArray assay1,4,16,23,24 as described in 
detail in Tang et al16. HPV16 copy number analysis was carried out using two methods that 
measure copies of HPV DNA: a modified quantitative PCR-MassArray(qPCR-MA) assay 




queries both E6 and E7. Both methods use GAPDH as an endogenous two copy/cell 
endogenous reference control. 
HPV E6 and E7 transcript analysis:  Two complementary reverse transcription-
PCR (RT-PCR) methods were used to evaluate and quantify the relative expression of the 
viral transcripts. The E6*I and E6*II alternate transcripts result from a single donor site at 
nucleotide (nt) 226 of the viral genome and two acceptor sites at nt 407 (E6*I) and at nt 
526 (E6*II).  To examine the expression of HPV16 E6 and E7 transcripts, primer sets were 
designed that specifically and discretely amplify the intact, non-spliced, full-length E6-E7 
transcript, the spliced E6*I-E7 transcript, and the spliced E6*II-7 transcript, as illustrated 
in Figure III.1  The full-length E6-E7 transcript was generated using a forward primer 
located within the region that is eliminated by splicing, while the transcripts for the 
alternate splice forms were generated using unique forward primers that span the 
respective splice junctions. (Primer sets are listed in Table SIII.1).  As a negative control, 
primers for GAPDH were used to confirm the absence of contaminating genomic DNA, 
indicated by a 158bp GAPDH amplicon product.  Quantitative RT-PCR (qRT-PCR) was 
 
Figure III.1. RT-PCR Strategy for Transcript-Specific E6-E7 Oncogene Evaluation in 
HPV16-Positive HNSCC Cell Lines. Primers within the spice region or across splice junctions 




subsequently performed using TaqMan assays designed to exclusively amplify each HPV 
early gene transcript: E1, E2, E5, non-spliced, full-length E6, spliced E6*I, spliced E6*II and 
E7. TaqMan chemistry works using forward and reverse primers together with a probe 
labeled with a fluorescent dye on the 5’ end and a signal quencher on the 3’ end. In the 
reaction, the primers and probe anneal to the denatured cDNA template, and Taq 
polymerase synthesizes the new DNA strand 5’ to 3’ along the template.  When the 
polymerase enzyme reaches the probe, its 5’ nuclease activity cleaves it, releasing the 
Figure III.2. Illustration of TaqMan Primers and Probes for Quantitative RT-PCR in 
HPV16-Positive HNSCC Cell Lines.  Dotted lines indicate splice sites, solid arrows represent 




fluorescent dye from the quencher and resulting in generation of a measurable signal. The 
primers and probe for the full-length E6 TaqMan assay anneal to the region between splice 
sites, and the TaqMan probes for the E6*I and E6*II alternate transcripts anneal to the 
particular splice junction for each, allowing for absolute specificity in the reactions. All of 
the TaqMan assays are illustrated in Figure III.2, and primer sequences are listed in Table 
SIII.2. A prepared GAPDH endogenous control primer/probe assay was used to quantify 
relative viral gene expression.  
Detection of Integrated Papillomavirus Sequences-Polymerase Chain Reaction 
(DIPS-PCR): Integration analysis was performed using a modified technique that is based 
on a previously published method25,26 and is illustrated in Figure III.3. Briefly, genomic 
DNA was isolated from each cell line, and digested with the restriction enzyme, Taqα1, 
which cuts the primary HPV16 viral genome only once at position 505 within E6 
(additional Taqα1 restriction sites have been described in HPV16 variants at positions 311 
and 2608) and cuts the cellular genomic DNA at approximately 1.5 million sites.  After 
ligating a double-strand DNA adapter (5’-CGCAACGTGTAAGTCTG-NH2-3’ annealed to 5’-
GGGCCATCAGTCAGCAGTCGTAGCCGGAT CCAGACTTACACGTTG-3’) to the overhanging 
ends of each fragment, linear PCR amplification with 11 viral-specific primers was followed 
by a second logarithmic PCR using 11 nested viral primers and a reverse adapter-specific 
primer (Table SIII.3). Thermocycling conditions used for both rounds of PCR included 3 
minute extension cycles that limited amplification of large (>3kb), episome-only fragments. 
PCR products were separated by agarose gel electrophoresis.  To search for a previously 
reported HPV insertion into 9q3114 that was not detected by DIPS-PCR in UPCI:SCC90, we 




from UPCI:SCC90 and the second cell line from the same patient, UPCI:SCC152 (Primers 
listed in Table SIII.4).  PCR products were separated by gel electrophoresis; bands were 
purified and sequenced with the appropriate primer sets.  
Sequence analysis of cellular genes with integrated virus: Fragments generated 
exclusively from non-integrated virus were excluded based on amplicon sizes predicted for 
episome-only bands, which were based on viral-specific primer locations in relation to the 
Figure III.3. Illustration of the HPV DIPS-PCR Method. 1. Genomic DNA is isolated from the 
sample, containing HPV in integrated, episomal, or both physical state; 2. Taqα1 restriction 
enzyme digests the DNA, resulting in linearized episomal virus (a), cellular-only (b), or viral-
cellular hybrid (c) fragments; 3. A dsDNA adapter is ligated to ends of the fragments; 4. 
Unidirectional, linear PCR amplifies from viral-specific primers (pink arrows) into cellular 
regions (d) or within the episomal virus (e); 5. A second round of PCR exponentially amplifies 
the products of the linear PCR with nested viral-specific primers (orange arrows) and a reverse 
primer that is specific to the adapter sequence (blue arrows); 6. Amplicons are separated and 
visualized by agarose gel electrophoresis, where episome-only viral products are distinguished 





Taqα1 restriction site in the viral genome. Viral-cellular amplicons were identified, excised 
from the gels, purified, and sequenced.  Viral integrations into known genes were verified 
by direct PCR and sequencing of the otherwise unmodified cell line genomic DNA, using 
primers specific to each viral and cellular region. 
Integration site transcript analysis:  Cell line RNA was evaluated for viral-cellular 
fusion transcripts and cellular gene transcripts affected by confirmed viral integrations.  
RT-PCR assays were used that amplified virus-cellular fusion transcripts from HPV ORFs 
into cellular gene exons, cellular gene exon-exon transcripts across the integration site, and 
distant cellular gene transcripts.   All amplified transcripts were separated by agarose gel 
electrophoresis sequenced for confirmation. 
 
Results 
HPV detection, identification, and copy number analysis: All seven cell lines 
were verified to contain HPV16 by PCR-MassArray. HPV16 copy number was estimated by 
PCR-MassArray and TaqMan assays (Table III.1) using the HPV16 cervical carcinoma cell 
lines CaSki (200-600 copies/cell) and SiHa (2 copies/cell) as reference cell lines.  HPV copy 
number ranged from a low 1-2 copies/cell in UM-SCC-104 and UPCI:SCC154 to hundreds of 
copies per cell in UPCI: SCC90, which has been previously reported to contain between 100 
and 150 copies of HPV1620.  The average for all cell lines was 100.6 HPV16 copies/cell. 
Metaphase chromosome spreads of UM-SCC-47 were examined by HPV16 FISH 
which revealed a strong signal, likely representing multiple copies of the viral genome, 




Cell Line Tumor Site 
HPV copies per cell  
Reported qPCR-MA TaqMan qPCR Average 
CaSki Cervix 200-600 182.8 423 302.9 
SiHa Cervix 2 2 2 2 
UD-SCC-2 Hypopharynx   47.1 38.1 42.6 
UM-SCC-47 Lateral Tongue   9.4 0.3 4.9 
UM-SCC-104 Floor of mouth   0.3 2.9 1.6 
UPCI:SCC90 Base of tongue  100-150 423.1 91.4 257.2 
UPCI:SCC152* Hypopharynx   46.8 309.5 178.2 
UPCI:SCC154 Base of tongue    1.8 0.8 1.3 
VU-SCC-147 Floor of mouth   230.5 206.1 218.3 
Table III.1. Cell Line HPV16 Copy Number as Determined by Quantitative HPV PCR-
MassArray (qPCR-MA) and TaqMan Quantitative PCR. * UPCI:SCC90 Recurrence  
the cell lines were examined for nuclear viral DNA by ISH (Figure III.4B-H) with deep blue 
hybridization signals that varied in intensity corresponding to the HPV copy number (Table 
III.1).  UM-SCC-104 (Figure III.4D) and UPCI:SCC154 (Figure III.4G) have very faint 
hybridization signals, consistent with low viral copy number. 
All seven HPV16-positive HNSCC cell lines express viral oncogene transcripts 
(Figure III.5).  The HPV16 E6 gene contains two introns that can be spliced out, generating 
alternate E6*I-E7 and E6*II-E7 transcripts that have been linked to increased expression of 
E7 at the expense of full length E627.  As shown in Figure III.5 A-G, all of the cell lines 
strongly express the viral oncogene transcripts and all express the alternate E6-E7 
transcripts, primarily E6*I, and to a lesser extent E6*II, with relatively low levels of full 
length E6 (qRT-PCR, bar graphs) or  full length E6-E7 (RT-PCR, gel images). These findings 
are consistent with the viral oncogenes as drivers of tumor development.  In all of the cell 





Figure III.4. HPV In Situ Hybridization in HNSCC Cell Lines. Panel A: UM-SCC-
47 fluorescence in situ hybridization for HPV16 in 2 cells, white arrows point to 
HPV signals, Panels B-H show hrHPV in situ hybridization indicated by dark blue 
signals. Panel B. UD-SCC-2, Panel C. UM-SCC-47, Panel D. UM-SCC-104, Panel E. 









Figure III.5. HPV Early 
Gene Transcript-Specific 
Quantitative RT-PCR and 
E6–E7 RT-PCR in HPV16-
Positive HNSCC Cell 
Lines. Bar graphs 
represent TaqMan 
quantitative PCR relative 
expression, and 
electrophoretic gel images 
represent E6-E7 RT-PCR. 
Panel A. UD-SCC-2, Panel 
B. UM-SCC-47, Panel C. 
UM-SCC-104, Panel D. 
UPCI:SCC90, Panel E. 
UPCI:SCC152, Panel F. 
UPCI:SCC154, Panel G. VU-
SCC-147.  Arrows indicate 
sizes of expected amplicon 
bands: HPVE6 
FullLength_E7=499bp, 
HPVE6*I_E7= 454bp, and 
HPVE6*II_E7= 338bp. M= 
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Figure III.6. Representative Cell Line DIPS PCR Gels.  Panel A. HPV-
E1a/Adapter primers, Panel B. HPV-E1c/Adapter primers,  Panel C. HPV-
E5a/Adapter primers, Panel D. HPV-L2a/Adapter primers, Panel E. HPV-
E2b/Adapter primers, Panel F HPV-E6a/Adapter primers, M=100 bp ladder.  
 
 
measured by TaqMan qRT-PCR relative to GAPDH.  Only UM-SCC-104 showed moderate 
levels of E2, but still had low levels of E1 expression.  These findings are consistent with 
disruption of the viral E1-E2 region.  
Detection of Integrated Papillomavirus Sequences-Polymerase Chain Reaction 
(DIPS-PCR): Separated amplicon DIPS-PCR bands are shown in the representative example 
gels in Figure III.6 A-F.  A total of 87 hybrid viral-cellular amplicons were isolated and 




Sequence analysis of cellular genes with integrated virus: Viral-host DNA 
fusions were identified by sequence analysis. The sequence reads mapped to viral-only 
sequence, viral-cellular hybrids as described below, or were unmapped due to poor 
sequence resolution. Diagrammatic representations of the viral rearrangements and 
insertion sites determined by this method are shown in Figure III.7A-H, and Table III.2 
summarizes the integration results for all seven cell lines, indicating the chromosome 
locus, known genes, and the regions of integration into the cellular gene.    Two 
rearrangements and two fusion events were detected in UD-SCC-2. The HPV16 internal 
rearrangements involved reverse HPVE6 joining forward LCR into a second copy of E6, and 
the second was HPV E1 directly joining the LCR. The first UD-SCC-2 integration was from 
HPV E2 into an intergenic region of chromosome 17q12, and a second fusing HPV E1 to 
intron 14 of JAK1. JAK1 is a large protein tyrosine kinase involved in the proper function of 
the interferon receptor complexes and signaling through the STAT1-4 pathway.  
UM-SCC-47 exhibited two HPV integration events with breakpoints within E2 each 
extending into TP63; one into TP63 reverse intron 10 and the second into TP63 exon 14.  As  
TP63 is located at chromosome 3q28, this is finding is consistent with the FISH result 
(Figure III.4A) showing a strong signal on the distal arm of an aberrant chromosome that is 
likely a t(3;7) chromosome rearrangement identified by Spectral Karyotyping (SKY) (Figure 
III.8).  Integration into TP63 has been observed in cervical cancers and Schmitz et al28 
reported a region of homology between the HPV16 E1 region and a segment of 
chromosome 3q28 within TP63 that may facilitate this integration.  TP63 is a homolog to 
TP53 and TP73, and is a tumor suppressor gene, functioning as both a sequence-specific 





Figure III.7. Diagrammatic Representation of Viral Rearrangements and Integration 
Events in HPV16-Positive HNSCC Cell Lines. Panel A. Linear organization of the HPV genome, 
Panel B. UD-SCC-2, Panel C. UM-SCC-47, Panel D. UM-SCC-104, Panel E. UPCI:SCC90, Panel F. 
UPCI:SCC152, Panel G. UPCI:SCC154, Panel H. VU-SCC-147. Arrow direction indicates orientation 
of genes. Solid colored arrows represent HPV, Dotted colored arrows indicate HPV sequence 
outside of mapped region, Dashed grey arrows are cellular intragenic regions, Dashed black 
arrows are cellular genes. The colors in the sequenced amplicons correspond to the color coded 













Locus Gene Gene Name Region Domain 
UD-SCC-2 
(F)E2  17q12 Intergenic       









(F)E2  3q28 TP63 Tumor protein p63 Exon 14 SAM domain 
UM-SCC-
104 
(F)E2  17q22 Intergenic       
(F)E2  17p11.2 Intergenic       
(R)E1 18q21.3 DCC 
Deleted in colorectal 
carcinoma 






(R)E1 9q31.1 Intergenic       





(R)E2 9q22.3 Intergenic       
(R)E1 9q31.1 Intergenic       
(F)LCR  3q23 ATR 
Ataxia telangiectasia 


















(F)E2  7q36 PTPRN2 
Protein tyrosine 
phosphatase, receptor 
N polypeptide 2  




(R)E2 2q33.2 TMEM237 
Transmembrane 







(R)E1 17q21 Intergenic       
(R)L2 3p21 Intergenic       
(R)E2  5p15.33 TERT 
Telomerase catalytic 
subunit 
Promoter Promoter region 
Table III.2. Summary of Integration Events in HPV16-Positive HNSCC Cell Lines.   (F) and (R)= 




repressor and activator. The p63 protein product of TP63 is involved in differentiation and 
cell-cycle regulation, as well as TGFβ and WNT signaling29.   
UM-SCC-104 exhibited multiple integration events including two HPV E2 integration 
events into intergenic regions of 17q22 and 17p11.2 (Figure III.7D). Additionally, in UM-
SCC-104, HPV E1 integrated into reverse DCC intron 1.  DCC is a receptor for netrin-1, and 
when not bound, functions as a tumor suppressor in the caspase-9 dependent apoptosis 
pathway.  DCC is located in a region of chromosome 18q that is frequently lost in squamous 
cell carcinomas30,31.    
UPCI:SCC90 and UPCI:SCC152 (tumors from the same patient) share the identical 
HPV rearrangement of HPV E6 connecting to reverse E6 into E7, as well as the same 
Figure III.8. Spectral Karyotyping (SKY) Chromosome Analysis of UM-SCC-47, Showing the 
t(3;7) Rearrangement.  UM-SCC-47 is a pseudotetraploid cell line from a male donor with 
several characteristic chromosomal rearrangements. 72,XX,+1,+del(1q),+2,+der(2)t(2;7), 
+der(2)t(2;7),+der(3)t(3;7),+i(5p),+der(5)t(5;7),+7,+8,+8,9, +10,+11,+der(12)t(8;12),+i(13q), 
der(13)t(13;16;22),der(13)t(13;21),+14,+14,+14,+15,i(17p),i(17q),+19,+19,+20,der(21) 





integration from HPV E1 into intron 1 of ETV6. These similarities are consistent with these 
being early events occurring before the primary tumor and recurrent populations diverged.  
ETV6 is a transcription factor involved primarily in development and hematopoiesis. Gene 
fusions involving ETV6 have been discovered in multiple hematological malignancies32, and 
there is evidence suggesting mutational inactivation of ETV6 in prostate carcinoma33.  
Interestingly, an ETV6 fusion oncogene was recently identified in a subset of salivary gland 
tumors34.   A previous study of UPCI:SCC90 reported a complex rearrangement of HPV that 
resulted in a rearranged chromosome 9 with fusions between HPV16 and 9q31.1 and 
9p2414.  Because we did not find this by integration by DIPS-PCR, we confirmed its 
presence by targeted PCR.  Sequence analysis revealed HPV E1 integrated into the same 
sequence as reported by Ragin et al.14, which was confirmed by BLAST analysis to map to 
9q31.1.   
In addition to the HPV E1- ETV6 integration, analysis of UPCI:SCC152 identified a 
viral rearrangement resulting in fusion of HPV E2 into an intergenic region of reverse 
chromosome 9q22.33, and a second integration from HPV LCR into ATR intron 36 on 
chromosome 3q23. ATR codes for a cell-cycle checkpoint protein kinase required for arrest 
and repair in response to DNA damage.  UPCI:SCC152 was also evaluated for the 9q31.1 
integration that was previously reported, and was detected by direct PCR exactly as in 
UPCI:SCC90.  The multiple viral integrations into chromosome 9 in UPCI:SCC90 and 
UPCI:SCC152 appear to be complex, involving both the 9p and 9q arms.  Thus far, our 





UPCI:SCC154 exhibited four integration events detected by DIPS-PCR, including  
HPV E1 into an intergenic region of chromosome 21p11.1, HPV E1 into reverse PGR, and 
two involving HPV E2; one into PTPRN2 intron 3 and the second into reverse TMEM237 
exon 14.  PGR is a steroid receptor for progesterone,  and participates in estrogen and 
glucocorticoid receptor pathways as well as signaling by binding to transcription factors 
such as NF-κB, AP-1 or STAT. Overexpression of PGR has been associated with disease-
related mortality and recurrence in breast and gastric cancers35,36.  PTPRN2 (protein 
tyrosine phosphatase, receptor type, N2) belongs to the transmembrane protein tyrosine 
phosphatase family, and is reported to be a tumor suppressor involved in the regulation of 
the cell cycle, as well as growth, differentiation, and oncogenic transformation. It has been 
demonstrated that PTPRN2 is hypermethylated and subsequently inactivated in squamous 
cell lung cancer37.   TMEM237 is a tetraspanin membrane protein that is thought to 
participate in the WNT signaling pathway.   
Three integration sites were identified in VU-SCC-147, one from HPV E1 into reverse 
chromosome 17q21, a second from HPV L2 into reverse chromosome 3p21, and a third 
from HPV E2 into reverse TERT (telomerase reverse transcriptase) in the promoter region.  
In a study that evaluated the frequency of TERT promoter mutations in 60 tumor types, 
squamous cells carcinomas of the head and neck were among the highest, with 17% of 
tumors having mutations in the promoter region of the gene38.   
These results show that in every cell line, viral integration into one or more cancer 
related genes was identified.  Table III.2 summarizes the integration results for all seven 




into the cellular gene.   Each of the viral integrations was confirmed by direct sequencing of 
the cell line genomic DNA.  
Integration site transcript analysis: Based on the DIPS-PCR integration results, 
RT-PCR assays were designed to assess virus-cellular fusion transcripts from HPV ORFs 
into cellular gene exons, cellular gene exon-exon transcripts across the integration site, and 
distant cellular gene transcripts.  Transcripts targeted for evaluation are represented in 
Figure III.9. HPV fusion transcript and cellular gene transcript RT-PCR amplicon products 
are shown in Figure III.10 and the results of transcript RT-PCR and sequence analysis are 
















Figure III.9. Diagram of Assays for Cell Line HPV Integration Site Transcript Analysis.  
             Purple line= HPV sequence,              Black dashed line= cellular exon following intron of 
integration,             Black solid line= cellular exon,      Orange triangle= viral-cellular junction,        
 Orange filled circle= spanning of integration site,        White filled circle= exon-exon 





In the UM-SCC-104 cell line, DCC transcripts within exon 1, across exons 1 and 2 that 
spanned the HPV integration site in intron 1, and across exons 2 and 3 were interrogated, 
but no DCC transcripts were detected. This suggests that one copy may have been 
disrupted by HPV integration and the other lost or silenced by methylation31.  
In both UPCI:SCC90 and UPCI:SCC152 cell lines, ETV6 transcripts were found 
outside of the intron 1 integration site, across exons 3 and 5. Interestingly, the ETV6 
transcript across exons 1 and 2, spanning the integration site in intron 1 was produced in 
UPCI:SCC152, but not in UPCI:SCC90. The transcripts that were generated in UPCI:SCC90 
and UPCI:SCC152 were all correct and in-frame.  Evaluation of the second integration event 
in UPCI:SCC152 revealed the correct, in-frame, ATR transcript present upstream of the 
integration site in intron 36 (across exons 34 to 36). However, the transcript across exons 
36 and 37, spanning the integration site, was generated but was not spliced in-frame.  
Furthermore, the ATR transcript across exons 37 and 38, downstream from the intron 36 
integration site, was not generated at all.   
In the UPCI:SCC154 cell line, neither the PGR transcript across exons 2 to 4, 
spanning the integration site in intron 3, nor the exon 1 transcript (outside of the 
integration region) was generated. There was no HPV/PTPRN2 fusion transcript produced, 
but the PTPRN2 transcript across exons 3 and 4, spanning the integration junction, was 
produced, as was the PTPRN2 transcript across exons 5 and 6, located downstream of the 
viral integration site. Both PTPRN2 exon-exon transcripts were in-frame.  Similarly, there 
was no HPV/TMEM237 fusion transcript, but the TMEM237 transcript generated within 
exon 13 that spanned the integration site was the correct, in-frame sequence.   In VU-SCC-






Figure III.10. Gel Analysis of Cell Line Integration Transcripts.  Blue 
text= transcript spanning integration site. Panel A. UD-SCC-2, Panel B. UM-
SCC-47, Panel C. UM-SCC-104, Panel D. UPCI:SCC90, Panel E. UPCI:SCC152, 





















The incidence of HPV-positive oropharyngeal cancer is increasing4,39,40.  Unlike 
cervical cancers that are detected early by Pap smear screening programs and often cured 
by colposcopy, there is no method for early detection of HPV-related head and neck cancer, 
and most such tumors present in an advanced state.  The incidence of invasive cervical 
cancer is declining in western countries secondary to early detection and intervention.  In 




Gene Region Transcript Analysis 
UD-SCC-2 (F)E1 JAK1 Intron 14 HPVE1_Ex15 
JAK1                      
Ex13-15 




(F)E2  TP63 Exon 14 
HPVE2_     
p63Ex14              
p63 Ex14 p63 Ex14 
(R)E2  TP63 Intron 10 
p63                  
Ex10-11 
    
UM-SCC-
104 
(R)E1 DCC Intron 1  DCC Ex1  DCC Ex1-2  DCC Ex2-3  
UPCI:SCC
90 
(R)E1 ETV6 Intron 1 
ETV6                 
Ex1-2  





(R)E1 ETV6 Intron 1 
ETV6                  
Ex1-2 
ETV6                   
Ex3-5 
  
(F)LCR ATR Intron 36 
ATR                     
Ex34-36 
ATR                        
Ex36-37 




(R)E1 PGR Intron 3 PGR Ex1 PGR Ex2-4    
(F)E2  PTPRN2 Intron 3  
HPVE2_           
PTPRN2 Ex3 
PTPRN2                 
Ex3-4 
PTPRN2        
Ex5-6 
(R)E2  TMEM237 Exon 13 
HPV E2_         
TMEM237 Ex13 
TMEM237             
Ex13    
VU-SCC-
147 
(R)E2  TERT Promoter TERT Ex1 TERT Ex3   
Table III.3. Summary of Integration Transcription Analysis in HPV16-Positive HNSCC Cell 
Lines.  (F) and (R)= Forward or Reverse viral orientation in relation to the cellular gene. 
Green text= Viral/cellular fusion transcript, Blue text=Transcript spans integration site, Grey 
shade=No transcript produced,      = Sequence spliced in-frame,      = Spliced sequence out of 
frame. 






cancers is expected to exceed that of cervix cancer in 201341.  Nevertheless, HPV-related 
oropharyngeal cancers are significantly more responsive to current therapeutic regimens 
than are HPV-negative cancers arising at the same anatomic sites2,42-45, prompting interest 
to reduce the intensity of treatment for this disease.  However, even with rigorous 
therapeutic approaches combining concurrent chemotherapy with radiation4,43,46, 20-30 
percent of HPV-positive cancers progress and become unresponsive to further treatment 
efforts.  Thus, it is important to understand why some tumors respond and others progress.   
Only a small number of HPV-positive head and neck cancer cell lines have been 
developed.  All were derived from tumors that failed to respond to therapy, and therefore 
may be representative of an aggressive subset of such tumors with features consistent with 
tumor progression.  All seven of the HPV16-positive head and neck cancer cell lines express 
p16INK4a strongly, and exhibit HPV E6-E7 viral oncogene expression, with dominant 
expression of the E6-E7 alternate transcripts.  In addition, all exhibit viral integration into 
the host cellular genome.  As shown in this study, the integration is often complex, with 
rearrangements and multiple cellular sites of integration involving different segments of 
the viral genome.  A somewhat surprising finding in our study was that in each cell line, the 
virus had integrated into cellular genes involved in cancer-related pathways. These 
findings suggest that assessment of cellular sites affected by viral integration in HNSCC may 
provide a second mechanism of oncogenesis through cellular gene disruption. Such a 
mechanism has been reported for oncogenesis by low-risk HPV types47 which lack the 
transforming ability of the high-risk E6 and E7 genes48.   
High-risk HPV integration has been widely examined in uterine cervix samples, and 




development49. HPV E2, a transcriptional repressor of E6 and E7, is frequently reported to 
be disrupted upon integration, resulting in proliferative expression of E6 and E733, 34.  In 
cervical cancer studies, as well as a small number of studies on HNSCC, viral integration has 
been found primarily in intragenic sites (~90% of the genome is intragenic), and in 
chromosome fragile sites14,15, although integration into cellular genes has also been 
reported in a minority of cases 26,28,50,51.  
In this study, we detected integration sites that differed from other investigators 
studying the same cell lines14.  Studies using DIPS-PCR may detect different sites of 
integration depending on the restriction enzymes used for DNA digestion, the amplification 
primers used in the PCR steps, the thermocycling conditions, and amplicon bands selected 
for sequence analysis.  The DNA digest is typically performed with Taqα1, which has a 
single restriction site within the HPV genome, or Sau3A1, with 10 restriction sites in the 
HPV genome. Both enzymes cut at numerous sites in the host cellular genome, but since the 
sites occur at different locations in the genome, the enzyme used will determine the cellular 
regions amplified in the assay. Subsequent PCR steps include viral-specific primers 
intended to amplify from the virus into the adjacent cellular sequence. The number and 
location of these primers direct generation of viral-cellular amplicon products; when few 
primers are used, or the primers are exclusive to the E2 region, integration events will be 
missed, particularly if the viral disruption occurs outside of the E2 region, or the viral-
specific primers are too far from the viral-cellular junction for efficient amplification and 
sequencing, or viral rearrangements preclude primer annealing. Furthermore, failure to 
detect integration events that involve multiple concatenated viral genomes may occur if 




discriminate within-viral from viral-cellular amplicon products.  In this study we selected 
and sequenced all bands less than 2kb to reduce detection of virus-only amplicons.  In spite 
of finding integrations sites previously unreported, our DIPS-PCR approach did not find the 
previously reported chromosome 9 intergenic insertion in UPCI:SCC90. However, using 
direct PCR we confirmed the presence of this insertion in the UPCI:SCC90 cells we studied.  
Another common method used to detect HPV integration, Amplification of Papillomavirus 
Oncogene Transcripts (APOT)52, which detects fusion transcripts from integrated HPV, has 
similar challenges in that this method will detect some but not all events due to limitations 
of viral primer location, possible gene rearrangement, absence of fusion transcripts, or 
insufficient assay sensitivity.  We confirmed the integration events that were discovered 
through DIPS-PCR by direct PCR and sequencing of each HPV-cellular fusion from cell line 
genomic DNA. This confirmation eliminated false-positive integration events that could 
have been induced through the substantial DNA manipulation of the DIPS-PCR method.  
Disruption of a cellular gene due to viral integration may or may not eliminate 
expression of the gene, depending on whether the second copy (or multiple copies, in the 
case of aneuploid tumor cells) is affected. The affected cellular gene may be upregulated, 
disrupted, or unaffected, contingent on strand orientation, as well as the precise viral-
cellular junction relative to sequence elements such as promoters and splice sites.   
Our assessment of cellular transcripts affected by viral integration provides 
important but limited information on the consequence of HPV integration on cellular gene 
expression. In the most straightforward cases, viral integration into DCC in UM-SCC-104 
and PGR in UPCI:SCC154, our analysis indicates that there are no transcripts generated for 




feasible that disruption of this gene through HPV integration could provide a growth 
advantage for tumor cells.  Similarly, the clinical relevance of PGR deficiency in these 
tumors is yet uncertain. 
The HPV integration into ATR is of special interest.  In this case the integration into 
intron 36 did not abrogate transcription across exons 34 and 36, but was associated with 
out of frame splicing in exons 36-37 and absence of transcription across exons 37 and 38.  
It will be necessary to expand the evaluation of each integration event to fully examine the 
effects on the complete cellular gene transcript. 
In the remaining cases, further investigation is needed to fully understand the effect 
HPV integration has on cellular gene expression. No in-frame HPV-cellular fusion 
transcripts were identified, and in nearly all cases, in-frame sequence of transcripts across 
viral-cellular integration junctions suggests the existence of at least one intact copy of the 
genes evaluated. In the majority of these cases, the viral integration occurs in an intron 
(UD-SCC-2 JAK1 Exon 13-15, UM-SCC-47 p63 Exon 10-11, UPCI:SCC90 ETV6 Exon 3-5, 
UPCI:SCC152 ETV6 Exon 3-5 and ATR Exon 36-37, and UPCI:SCC154 PTPRN2 Exon 3-4), 
and we speculate that perhaps the virus is contained within the intron, and is spliced out 
upon cellular RNA processing. A probable explanation for retained exon-exon transcription 
of genes with integrated HPV is the presence of additional unaffected gene copies that can 
generate the intact transcripts. Another possibility in cases with viral integration into 
either cellular introns or exons may be unanticipated splicing from upstream viral regions 
into cellular exons, such that the transcripts generated do not contain viral regions 
proximal to the DNA integration sites.  In addition to further analysis of the cellular 




the integration site in order to determine whether the virus has integrated into 2 different 
sites in possibly rearranged chromosomes.  
The discovery of hrHPV integration into cancer-related genes in all seven of the 
HNSCC cell lines examined is remarkable, and provides a basis for further investigation of 
this finding as a possible mechanism of tumor progression and response to therapy. 
However, ascertaining the true impact of viral integration on the expression or activity of 
cellular genes is complicated by both irregular patterns of viral integration (multiple 
concatenated copies, alternating forward/reverse copies, and rearrangements within 
integrated viral copies) and atypical, disordered, and likely aneuploid cellular genomes.  
Comprehensive investigation to understand the specific cellular alterations caused 
by HPV integration may provide insight for development of alternate therapies for non-
responsive tumors.  Implementation of viral integration analysis to differentiate responsive 
from non-responsive HPV-positive head and neck tumors may provide further insight into 
the factors that distinguish responsive and non-responsive oropharyngeal cancers.  This 
understanding will be necessary to avoid under-treatment of patients selected to receive 
reduced-intensity therapy and to improve treatment of those with more aggressive tumors 
who fail to respond to intensive treatment. 
We postulate that integration into gene poor or chromosome fragile sites probably 
occurs in the majority of HPV-driven cancers, but that secondary integration events into 
cellular genes, such as tumor suppressor genes or genes involved in cancer pathways may 
be linked to more aggressive malignant behavior.  Design of a model to distinguish 
responsive from non-responsive HPV-positive head and neck tumors assumes viral 




region, and alternate E6*I, E6*II transcription, which lead to increased viral oncogene 
expression53-55.  In such a model, tumors with HPV integration into intergenic chromosome 
sites or fragile sites are maintained as primarily HPV-driven tumors and are likely to 
respond to current or reduced-intensity treatment, but tumors with HPV integration into 
cancer-related genes may acquire secondary alterations in cellular gene expression or 
dysfunction, resulting in a more aggressive malignant phenotype resistant to current 





Figure III.11. Proposed Model for Differentiation of Responsive and Non-Responsive 

































Table SIII.1. RT-PCR Assay Primer Sequences and Corresponding 




























































Table SIII.2. TaqMan Quantitative RT-PCR Assay Primer and Probe Sequences for Viral 








Forward Primer 1 
Sequence 



































































































































Table SIII.4. HPV16 and Chromosome 9q31.1 PCR Primer Sequences 
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High-Risk Human Papillomavirus Integration into Cellular Genes: Association with 
Recurrence and Progression in Oropharyngeal Squamous Cell Carcinoma 
 
Abstract 
High-risk HPV (hrHPV) is a known driver of carcinogenesis; multiple studies have 
shown that hrHPV is now the leading etiologic factor in oropharyngeal cancer.  HPV-
positive oropharynx tumors generally respond well to current therapies, with complete 
recovery in approximately 80% of patients. However, it is not yet known why a subset of 
HPV-positive oropharyngeal tumors fails to respond to treatment, with 20% of patients 
recurring within 5 years. We and others have hypothesized that viral integration into the 
host cellular genome may contribute to additional mechanisms of carcinogenesis. 
Furthermore, we have previously demonstrated evidence of hrHPV integration into cancer-
related genes in head and neck squamous cell carcinoma (HNSCC) cell lines.  
This study examines hrHPV oncogene expression for confirmation of viral activity 
and integration into the host cellular genome in oropharynx tumors with known outcome, 
to evaluate the predicative potential of viral integration sites in HPV-driven oropharynx 
tumors.  Quantitative reverse-transcription PCR was used to assess viral oncogene 
alternate transcripts.  Detection of integrated papillomavirus sequences (DIPS-PCR) and 
sequencing was used to establish viral integration and map specific sites of viral 
integration into the host cellular genome. Transcript analysis of viral integration into 





expression.  Ten oropharynx tumors were assessed, including 5 tumors that responded 
well to therapy and 5 tumors that recurred after failing to respond to therapy. 
All of the tumors demonstrated active viral oncogenesis, indicated by expression of 
HPV E6 and E7 oncogenes and alternate E6 splicing.  In the responsive tumors, HPV 
integration was found in extragenic chromosome regions, as well as one integration event 
into a known cancer-related gene, TP63. In the recurrent tumors, two HPV integration 
events were found in extragenic regions on chromosome 10, and each recurrent tumor 
exhibited HPV integration into known cellular genes, including cancer-associated genes 
TNFRSF13B, SCN2A, SH2B1, UBE2V2, SMOC1, NFIA, and SEMA6D.  The difference in cellular 
sites of HPV integration seen between responsive and recurrent hrHPV-driven tumors may 
suggest that viral integration into intergenic regions is associated with more responsive 
tumors and viral integration into cancer-related genes is associated with those more likely 
to require additional or alternate therapies.  
 
Introduction 
High-risk human papillomaviruses (hrHPV) are known factors in the etiology of 
head and neck squamous cell carcinoma, particularly in association with the increasing 
incidence of oropharynx cancers.   In oropharyngeal tumors, hrHPV is associated with 
better prognosis, suggesting that hrHPV-positive tumors may be responsive to alternate 
therapies that are more tolerable than those currently used1-10.  However, a reduction in 
treatment intensity is precluded by our current inability to distinguish the responsive 
tumors from the minority of HPV-positive oropharynx tumors that fail to respond to 





Carcinogenesis in hrHPV-induced tumors is driven by sustained expression of viral 
E6 and E7 oncogenes. The HPV16 E6 gene contains two introns that can be spliced out, 
generating alternate E6*I-E7 and E6*II-E7 transcripts that have been linked to increased 
expression of E7, considered the more potent oncoprotein, at the expense of full length 
E611-16. The E6*I and E6*II alternate transcripts result from a single donor site at 
nucleotide (nt) 226 of the viral genome and two acceptor sites at nt 407 (E6*I) and at nt 
526 (E6*II) (Figure IV.1).  It is not known whether viral integration contributes to 
progression or resistance to therapy by augmenting the viral oncogene expression or 
through additional mechanisms. Secondary carcinogenic mechanisms of viral integration 
could include disruption of tumor suppressor genes or upregulation of genes that promote 
cell-cycle progression.    Integration of hrHPV into the host cellular genome has been 
reported to be associated with high E6 and E7 transcription and carcinogenic progression 
from cervical intraepithelial neoplasia (CIN) to invasive disease in many cervical cancer 
studies17-20.   Cellular sites of viral integration in cervical cancer are primarily into 
extragenic regions or chromosome common fragile sites21-23, but there are studies that 
report viral integration into known genes in cervical cancer24-27. 
We have previously demonstrated transcriptionally-active hrHPV integration into 
known cancer-related genes in all seven available HPV16-positive HNSCC cell lines, which 
are derived from tumors that failed to respond to therapy.  We postulate that integration 
into important cellular genes may be a secondary driver of more highly malignant HPV-
positive head and neck tumors, and may be a predictive tool to differentiate responsive and 







Tumor specimens:  We evaluated ten HPV-positive oropharyngeal tumors from 
patients who had provided written informed consent to investigate their tissue under a 
study approved by the Institutional Review Board for the University of Michigan medical 
school. Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor 
cores using the DNeasy Blood and Tissue Kit (Qiagen) or fresh-frozen tumor sections using 
a standard phenol extraction. Tumor tissue was microdissected for RNA from fresh-frozen 
tumor sections immediately following histological evaluation. Total RNA was isolated using 
the RNeasy Mini Kit with QIAzol (Qiagen), followed by on-column DNase treatment.  
HPV genotyping and copy number analysis: hrHPV genotyping was performed on 
DNA from all tumors using the HPV PCR-MassArray assay3,28-31.  Type-specific TaqMan 
quantitative PCR was used to determine HPV copies per cell, assessing both E6 and E7 
amplicons, with a GAPDH assay as an endogenous two copy/cell endogenous reference 
control. 
HPV E6 and E7 transcript analysis: HPV16 E6 and E7 transcripts were evaluated 
by reverse-transcription PCR (RT-PCR) with gel electrophoresis and TaqMan quantitative 
RT-PCR.  To analyze the expression of HPV16 E6 and E7, transcript-specific assays were 
used that exclusively amplify each product: the intact, non-spliced, full-length E6-E7 
transcript, the spliced E6*I-E7 transcript, and the spliced E6*II-E7 transcript, as illustrated 
in Figure IV.1 (Primer sets are listed in Table SIV.1).  An assay for human endogenous 
GAPDH was included to verify the absence of contaminating genomic DNA.  Quantitative 
RT-PCR was performed using similar transcript-specific TaqMan assays that individually 





E6*II and E7 (Assays are portrayed in Figure IV.2 and primer sequences are listed in Table 
SIV.2). A TaqMan quantitative assay for GAPDH was included as an endogenous control to 
calculate relative viral gene expression.  
Detection of Integrated Papillomavirus Sequences-Polymerase Chain Reaction 
(DIPS-PCR): Viral integration was evaluated using an adaptation (illustrated in Figure 
III.3) of the DIPS-PCR method previously published23,25. Genomic DNA from each tumor 
was subjected to Taqα1 restriction enzyme digestion, producing fragmented DNA. There 
are  approximately 1.5 million Taqα1 restriction sites within the human cellular genome, 
but only one in the non-variant HPV16 genome, located in the E6 open reading frame (ORF) 
at nucleotide 505 (nt 505).  Additional HPV16 Taqα1 restriction sites have been described 
in HPV16 variants at positions 311 and 2608.  Following restriction digest, a ligation 
reaction attached a double-strand adapter oligo (5’-CGCAACGTGTAAGTCTG-NH2-3’ 
annealed to 5’-GGGCCATCAGTCAGCAGTCGTAGCCGGAT CCAGACTTACACGTTG-3’) to the 
overhanging ends of each fragment. Linear amplification of the ligated fragments was 
performed using 11 viral-specific primers, generating amplicons that originate in the viral 
genome, extend into adjacent cellular sequence, and terminate at the end of the adapter 
Figure IV.1. RT-PCR Strategy for Transcript-Specific E6-E7 Oncogene Evaluation in 
HPV16-Positive HNSCC Tumors. Primers within the splice region or across splice junctions 





oligo (Primers are listed in Table SIV.3). This was followed by a second, logarithmic, PCR 
using 11 nested viral primers with a reverse adapter-specific primer (Primers are listed in 
Table SIV.3). Thermocycling conditions used for linear and exponential PCR included 3 
minute extension cycles, allowing limitation of  amplicon size to 3kb or less, therefore 
excluding production of any of large (>3kb), episome-only fragments.  PCR products were 
separated by gel electrophoresis.  
Sequence analysis of HPV16 integration products: Viral-cellular fragments were 
distinguished from episomal virus fragments based on predicted viral-only amplicon sizes 
of 2750bp or larger (Table SIV.3). DIPS-PCR amplicons of approximately 2500bp or smaller 
were identified, the corresponding bands were excised, and the amplicons were purified 
and sequenced. Integration events into known cellular genes were confirmed by direct PCR 
and sequencing of the original tumor genomic DNA, using primers designed for each viral 
and cellular region. 
Figure IV.2. Illustration of TaqMan Primers and Probes for Quantitative RT-PCR in 
HPV16-Positive Tumors.  Solid arrows represent primers and dashed arrows represent 

















Table IV.1. Responsive and Recurrent Tumor 
HPV16 Copy Number as Determined by TaqMan 
Quantitative PCR. 
Integration site transcript analysis:  RT-PCR assays were designed to amplify 
viral-cellular fusion transcripts and cellular transcripts from tumor RNA in cases expected 
to be altered by confirmed viral integration into known cellular genes. Assays included 
virus-cellular fusion transcripts (although expected only in the single case where the 
integration into the cellular gene followed the same orientation as the virus) from HPV 
ORFs into cellular gene exons, cellular gene exon-exon transcripts spanning the integration 
site, and exon-exon or within-exon transcripts outside of the integration site region.  All 
successfully amplified transcripts were sequenced for verification. 
 
Results 
HPV genotyping and copy number analysis:  All 10 tumors were positive for 
HPV16 and negative for all other hrHPV types included in the PCR-MassArray assay. HPV16 
copy number for the responsive tumors ranged from 16 to over 500 copies per cell; tumor 
1733 had 22.5 HPV16 copies per cell, tumor 1769 had 475.6 copies per cell, tumor 1804 
had 161.1 copies per cell, tumor 
1971 had 538.9 copies per cell, and 
tumor 2148 had 16.1 copies per 
cell. The recurrent tumors had 
overall lower values, ranging from 
6 to nearly 300 HPV16 copies per 
cell; tumor 0732 had 110.7 HPV16 
copies per cell, tumor 0843 had 





had 297.9 copies per cell, tumor 2049 was the lowest with 6.3 copies per cell, and tumor 
2238 had 14.0 copies per cell (Table IV.1).  The average viral copy number was 242.8 for 
the responsive tumors, and 92.6 for the recurrent tumors. 
HPV E6 and E7 transcript analysis:  HPV16 E6 and E7 transcripts were expressed 
in all ten HPV16-positive tumors.  In both responsive and recurrent tumor groups, the most 
abundant transcript in four of the five tumors was the alternate E6* transcript, which is 
known to be expressed in hrHPV-transformed tumor cells. In these tumors, the full length 
E6 transcript was much lower than the E6*I transcript; the exceptions were responsive 
tumor 1971 and recurrent tumor 0732, where the full length E6 transcript exhibited the 
highest level of expression (Figures IV.3 and IV.4).  
Detection of Integrated Papillomavirus Sequences-Polymerase Chain Reaction 
(DIPS-PCR): All ten HPV16-positive tumor specimens demonstrated viral integration; 
representative DIPS-PCR gels for responsive and recurrent tumors are shown in Figures 
IV.5 and IV.6, respectively.  A total of 207 hybrid viral-cellular amplicons were isolated and 
sequenced.  Among the 99 amplicons generated from the responsive tumors, there were 20 
for tumor 1733, 22 for tumor 1769, 26 for tumor 1804, 26 for tumor 1971, and 5 for tumor 
2148. The 108 amplicons from the recurrent tumors included 30 for tumor 0732, 23 for 
tumor 0843, 13 for tumor 1040, 18 for tumor 2049, and 24 for tumor 2238.  Viral-host DNA 
fusions were identified by sequence and BLAST analysis. The sequence reads mapped to 
viral-only sequence, viral-cellular hybrids as described below, or were unmapped due to 
poor sequence resolution. Diagrammatic representations of the viral integration events 
identified are depicted in Figure IV.7 for responsive tumors and Figure IV.8 for recurrent 









Figure IV.3. HPV Oncogene 
Transcript- Specific Quantitative RT-
PCR and E6–E7 RT-PCR in HPV16-
Positive Responsive Tumors.   
Bar graphs represent TaqMan 
quantitative PCR relative expression, 
and electrophoretic gel images 
represent E6-E7 RT-PCR.  Panel A. 1733, 
Panel B. 1769, Panel C. 1804, Panel D. 
1971, Panel E. 2148. Arrows indicate 
sizes of expected amplicon bands:  
HPVE6 FullLength_E7=499bp, 
HPVE6*I_E7= 454bp, and HPVE6*II_E7= 
338bp. NO RT=no reverse transcriptase 










Figure IV.4. HPV Oncogene Transcript- 
Specific Quantitative RT-PCR and E6–
E7 RT-PCR in HPV16-Positive 
Recurrent Tumors.   
Bar graphs represent TaqMan 
quantitative PCR relative expression, and 
electrophoretic gel images represent E6-
E7 RT-PCR.  Panel A. 0732, Panel B. 0843, 
Panel C. 1040, Panel D. 2049, Panel E. 
2238.  Arrows indicate sizes of expected 
amplicon bands:  
HPVE6 FullLength_E7=499bp, 
HPVE6*I_E7= 454bp, and HPVE6*II_E7= 
338bp. NO RT=no reverse transcriptase 






and recurrent tumors, respectively, indicating the chromosome locus, known genes, and 
the regions of integration into the cellular gene.    
Sequence analysis of integration events in responsive tumors: Eleven of the 
twelve HPV integration events identified in the responsive tumors involved intergenic 
chromosome regions.  Tumor 1733 had an HPV E2 integration into 2p16, which is a known 
chromosome fragile site32; tumor 1979 had 3 integration events, HPV E2 into 9q21, HPV L1 
into 16q11.2, and another L1 into 4q27; four integration events were identified in tumor 
1804, HPV E1 into 6q16, HPV L2 into 10p11.1, HPV E5 into 16q11.2, and HPV E2 into 
Figure IV.5. Representative Responsive Tumor DIPS PCR Gels.  Panel A. HPV-E1a/Adapter 
primers, Panel B. HPV-E1b/Adapter primers,  Panel C. HPV-E1c/Adapter primers, Panel D. HPV-







16q11.2; tumor 2148 had a single integration of HPV L2 into 7p22, which is a known 
chromosome fragile site32; and tumor 1971 had three integrations, HPV E1 into 
chromosome fragile site 7p22.332, L2 into 4p16.3, also a known chromosome fragile site32, 
and HPV L1 into 3q28, where the virus inserted into intron 4 of TP63, the gene for tumor 
suppressor protein 63.  This integration site is located within the region that codes for the 
DNA binding domain of the protein.  Interestingly, we observed HPV integration into this 
same gene in the HNSCC cell line UM-SCC-47, where HPV E2 inserted into both intron 10   
Figure IV.6. Representative Recurrent Tumor DIPS PCR Gels.  Panel A. HPV-E1a/Adapter 
primers, Panel B. HPV-E1b/Adapter primers,  Panel C. HPV-E1c/Adapter primers, Panel D. HPV-








Figure IV.7. Schematic Representation of Integration Events in HPV16-
Positive Responsive Tumors. Panel A. Linear organization of the HPV genome, 
Panel B. 1733, Panel C. 1769, Panel D. 1804, Panel E. 1971, Panel F. 2148. Arrow 
direction indicates orientation of genes. Solid colored arrows represent HPV, 
Dotted colored arrows indicate HPV sequence outside of mapped region, Dashed 
grey arrows are cellular intragenic regions, Dashed black arrows are cellular 
genes. The colors in the sequenced amplicons correspond to the color coded viral 






and exon14 of TP63. Viral integration into TP63 has also been reported in cervical cancers, 
and susceptibility for integration into this gene may be due to short segments of 
homologous sequence shared by HPV E1 and chromosome 3q28 within the TP63 gene24.  
TP63 belongs to the p53 family of tumor suppressor genes, and is a sequence-specific DNA 
binding transcriptional repressor and activator. The p63 protein participates in TGFβ and 
WNT signal transduction as well as differentiation and cell-cycle regulation33, and as such, 
HPV integration into the TP63 gene could cause disruption of these processes and may 





Locus Gene Gene Name Region Domain 
1733 (F)E2 2p16 Intergenic   
1769 
(F)E2 9q21 Intergenic   
(R)L1 16q11.2 Intergenic   
(R)L1 4q27 Intergenic   
1804 
(R)E1 6q16 Intergenic   
(F)L2 10p11.1 Intergenic   
(F)E5 16q11.2 Intergenic   
(F)E2 16q11.2 Intergenic   
1971 
(F)E1 7p22.3 Intergenic   
(R)L2 4p16.3 Intergenic   







2148 (F)L2 7p22  Intergenic   
Table IV.2. Summary of Integration Events in HPV16-Positive Responsive 






Sequence analysis of integration events in recurrent tumors: The recurrent 
tumors exhibited viral integration into both intergenic and genic regions. Tumor 0732 had 
integration from HPV E2 into an intergenic region at 10p11.1, as well as HPV L2 into 
17p11.2, inserting at intron 3 of TNFRSF13B, the gene coding for a member of the tumor 
necrosis factor receptor superfamily. This viral integration occurs within the region that 
produces the extracellular topological domain of the receptor protein, which participates in 
immunity by interacting with a TNF ligand. TNFRSF13B induces B-cell maturation and 
differentiation and activates multiple transcription factors, including NFAT, AP1, and NF-
κB.  It has been reported that hematological malignancies are induced by B-cell survival 
and aberrant proliferation caused by dysregulated signaling by TNFRSF family members34, 
but how this pathway may be involved in HNSCC is not clear.   
A single integration event was identified in tumor 0843, HPV L2 into 2q24.3, at 
intron 16 of SCN2A, which codes for the voltage-gated type II sodium channel α subunit. 
This integration takes place in the second helical transmembrane S6 region of the protein, 
which participates in a complex for action potential initiation and propagation in excitable 
cells, as well as proliferation, migration, and adhesion in non-excitable cells35. It has been 
reported that differential expression of voltage-gated sodium channels is associated with 
the metastatic activity of multiple malignancies such as leukemia and prostate, breast, and 
lung cancer, and these ion channels are currently being investigated as targets for cancer 
therapies35-38. Additionally, DIPS-PCR and sequencing revealed an HPV early gene 
rearrangement in tumor 0843, where the latter half of E6 was duplicated and joined within 







Figure IV.8. Schematic Representation of Rearrangements and Integration 
Events in HPV16-Positive Recurrent Tumors. Panel A. Linear organization of the 
HPV genome, Panel B. 0732, Panel C. 0843, Panel D. 1040, Panel E. 2049, Panel F. 
2238. Arrow direction indicates orientation of genes. Solid colored arrows represent 
HPV, Dotted colored arrows indicate HPV sequence outside of mapped region, 
Dashed grey arrows are cellular intragenic regions, Dashed black arrows are cellular 
genes. The colors in the sequenced amplicons correspond to the color coded viral 





Tumor 1040 had integration of HPV L2 into an intergenic region of 10p11.1, as well 
as HPV L1 into 16p11.2, at intron 3 of SH2B1, the gene for SH2B adapter protein 1. This is a 
mediator protein for tyrosine kinase receptors, and is involved in Janus kinase (JAK) and 
receptor tyrosine kinase signaling pathways.  Based on the common pathway, 
consequences of HPV integration into SH2B in this tumor could be similar to potential 





Locus Gene Gene Name Region Domain 
0732 
(R)E2 10p11.1 Intergenic   








0843 (F)L2 2q24.3 SCN2A 
Sodium channel, 
voltage-gated, 





of repeat II region 
1040 
(R)L2 10p11.1 Intergenic   







































Table IV.3. Summary of Integration Events in HPV16-Positive Recurrent Tumors. (F) 





mediates interferon receptors and STAT signaling, and viral integration may be associated 
with loss of interferon signaling within transformed cells39.   
Tumor 2049 had two integration events, the first involving a rearrangement of HPV 
E1 (where a duplicated region of E1 was inserted into E1 upstream of the integration) into 
8q11.21, at intron 1 of UBE2V2, which codes for ubiquitin-conjugating enzyme E2 variant 2 
(Figure IV.8E). The protein product of UBE2V2 mediates transcriptional activation of target 
genes, regulates cell cycle progression and cellular differentiation, and is involved in DNA 
repair and cell survival after DNA damage.  Deregulation of UBE2V2 expression has been 
reported to be associated with gastric cancer40, and in ER-positive/HER2-negative breast 
cancer, UBE2V2 was linked to poor prognosis41.   The second integration even identified in 
tumor 2049 was HPV E1 into 14q24.1, at intron 1 of SMOC1, the gene for SPARC-related 
modular calcium binding 1. SMOC1 codes for a secreted protein localized to the basement 
membrane that is involved in cellular differentiation, and has been associated with brain 
cancer42. 
Two integration events were identified in tumor 2238, the first was comprised of a 
rearrangement within HPV, where the L2/L1 overlapping region was inserted into the E1 
ORF and inserted into 1p31.3, at intron 9 of NFIA, which codes for nuclear factor I/A. The 
NFIA protein product is a sequence-specific transcription factor that regulates numerous 
viral and cellular genes, and is independently proficient in activating cellular transcription 
and replication.  It was recently reported that an investigation of acute erythroid leukemia 
containing t(1;16)(p31;q24) uncovered a gene fusion between NFIA/CBFA2T343.  The 
second integration in tumor 2238 was HPV E2 into 15q21.1, at intron 4 of SEMA6D, the 





characterized as an axon guidance molecule, but has more recently been shown to 
participate in differentiation, organogenesis, and angiogenesis, mediated by Plexin-A1 as 
the major Sema6D-binding receptor44,45.  Furthermore, it has been reported that the 
Sema6D/Plexin-A1 complex binds VEGFR-2 to mediate survival and anchorage-
independent growth of tumor cells45,46.   
HPV integration into the intergenic chromosome region 16q11.2 was identified 3 
times among the responsive tumors examined; once in tumor 1769 and in two different 
events in tumor 1804. A second intergenic region was involved in 3 integration events 
among the tumors evaluated; responsive tumor 1804 and recurrent tumors 0732 and 1040 
all exhibited viral integration into chromosome 10p11.1.  These parallels suggest that there 
may be sequence or structural similarities that increase the probability of viral integration 
into these regions.  Each integration into a cellular gene was confirmed by direct PCR and 
sequencing of the tumor genomic DNA, eliminating possible false-positive integration 
events induced by the DIPS-PCR method.   
Integration site transcript analysis: Based on the integration results from the 
DIPS-PCR analysis, assays for integration site transcript analysis were designed as 
illustrated in Figure IV.9. Results of the transcript analysis (electrophoretic gel images of 
transcript amplicons) are shown in Figure IV.10, and Table IV.4 lists a summary of 
transcript RT-PCR and sequencing results.  In responsive tumor 1971, a fusion transcript 
between HPV L1 and TP63 exon 4 was not produced. The transcript across TP63 exons 4 
and 5, spanning the viral integration site in intron 4, was produced, and the sequence was 
in-frame. Additionally, the transcript across TP63 exons 5 and 6 (outside of the integration 






 In the recurrent tumor 0732, no fusion transcript was generated between HPV L2 
and TNFRSF exon 3. The transcript across TNFRSF exons 3 and 4, spanning the viral 
integration site in intron 3, as well as the TNFRSF transcript across exons 4 and 5, outside 
of the integration site, was generated and the both sequences were in-frame.  
No fusion transcript was created in tumor 0843 between HPV L2 and cellular SCN2A 
exon 17. There was a transcript generated across the integration site in intron 16, but the 
transcript sequence did not map to any region of SCN2A. Sequence analysis of this 
Figure IV.9. Diagram of Assays for Tumor HPV Integration Site Transcript Analysis.  
             Blue line= HPV sequence,              Black dashed line= cellular exon following intron of 
integration,             Black solid line= cellular exon,      Pink triangle= viral-cellular junction,        
 Pink filled circle= spanning of integration site,        White filled circle= exon-exon boundary 








     
Figure IV.10. Gel Electrophoresis of Tumor Integration Transcript Analysis. Blue text 
indicates transcript spanning integration site. Panel A. Responsive tumor 1971, Panel B. 
Tumor 0732, Panel C. Tumor 0843, Panel D. Tumor 1040, Panel E. Tumor 2049, Panel F. 






transcript amplicon identified a portion of HPV L1 flanked on one side by the cellular gene 
for the ATP-binding cassette, sub-family A, member 12 (ABCA12) located on chromosome 
2q34, and on the other side by an intergenic region of chromosome 1q32. Furthermore, 
there was no transcript generated when SCN2A was queried downstream from the 
integration event, across exons 18 and 19.  
In recurrent tumor 1040, there was no fusion transcript generated between HPV L1 
and cellular SH2B exon 3. There were, however, transcripts generated across SH2B exons 3 
and 4 (spanning the intron 3 integration site), and within exon 5 (outside of the integration 























In both integration events in recurrent tumor 2049, fusion transcripts were 




Gene Region Transcript Analysis 
1971 (R)L1 TP63 
Intron 
4 
HPV L1_            
p63 Ex4 
p63                  
Ex4-5 
p63              
Ex5-6 
0732 (R)L2 TNFRSF13B 
Intron 
3 
HPV L2_     
TNFRSF Ex3 
TNFRSF          
Ex3-4 
TNFRSF    
Ex4-5 
0843 (F)L2 SCN2A 
Intron 
16 
HPV L2_        
SNC2A Ex17 
SNC2A          
Ex16-17 
SNC2A      
Ex18-19 
1040 (R)L1 SH2B 
Intron 
3 
HPV L1_         
SH2B Ex3 
SH2B                
Ex3-4 






HPV E1_     
UBE2V2 Ex1 
UBE2V2         
Ex1-2 





HPV E1_      
SMOC1 Ex1 
SMOC1           
Ex1-2 






HPV L1_          
NFIA Ex9 
NFIA                
Ex9-10 





HPV E2_     
SEMA6D Ex4 
SEMA6D         
Ex4-5 
SEMA6D     
Ex5-6 
Table IV.4. Summary of Integration Transcription Analysis in HPV16-Positive Tumors.   
(F) and (R) = Forward or Reverse viral orientation in relation to the cellular gene.                     
Green text= Viral/cellular fusion transcript, Blue text=Transcript spans integration site, Grey 
shade=No transcript produced,      = Nonsense sequence, no alignment,      = Sequence was 








portion of HPV L1 was fused with the entire UBE2V2 exon 1, and the distal end of the 
transcript amplicon included the expected region of HPV E1 attached to chromosome 
17q11.2, with nonsense sequence between. Both the UBE2V2 transcript across exons 1 and 
2, spanning the integration site in intron 1, as well as the transcript outside of the 
integration region across exons 2 and 3 were produced and the sequences were spliced  
in-frame. The second fusion transcript in tumor 2049 was sequenced and contained SMOC1 
exon 1 linked to chromosome 3p23, followed by nonsense sequence. There were 
transcripts generated across SMOC1 exons 1 and 2 (spanning the intron 1 integration) and 
exons 3 and 4 (outside of the integration region), but the transcript sequences did not 
contain any homology to SMOC1, and were determined to be nonsense sequence.  
In the recurrent tumor 2238, fusion transcripts were not generated between either 
HPV L1 and NFIA or HPV E2 and SEMA6D. There were also no transcripts generated across 
NFIA exons 9 and 10, spanning the intron 9 integration, or across SEMA6D exons 4 and 5, 
spanning the intron 4 integration site. The NFIA transcript across exons 10 and 11, outside 
of the integration site, was produced and the sequence was in-frame. The SEMA6D 
transcript across exons 5 and 6, outside of the integration site, was also generated, but was 
found to be nonsense upon sequence analysis. 
 
Discussion 
The incidence of HPV-positive oropharyngeal cancer is rising, and there remains a 
lack of understanding around factors that determine or influence tumor response to 
treatment1-10,47-50. There is significant interest in reducing treatment intensity for patients 





of non-responsive tumors above the current 20-30% of patients who fail intensive 
concurrent therapy2,51-53.  Based on our previous work and what is known from HPV in 
cervical cancer, we examined transcriptional activity and viral integration of hrHPV in 
responsive and recurrent tumors to determine whether these factors might be useful as 
clinically-relevant factors to predict response.   
The ten tumors studied were positive for HPV16 and negative for all other high-risk 
HPV types assessed.  HPV copy number was established for each tumor; the ranges of viral 
load values were similar for responsive and recurrent tumors (16-539 copies/cell for 
responsive tumors, 6-298 copies/cell for recurrent tumors). It is important to note that the 
values obtained for viral copy number may not be exact because the tumor DNA was 
extracted from tissue cores that may have contained normal cells. Nevertheless, the 
average viral copy for the responsive tumors (242.8 copies/cell) was more than twice that 
of the recurrent tumors (92.6). While the small number of tumors and wide ranges of copy 
number values limit our ability to draw conclusions from this result, it does agree with our 
hypothesis that earlier tumors are more likely to contain high numbers of episomal HPV, 
and more advanced cancers are more likely to have lost episomal copies and be driven by 
fewer copies of integrated virus.  
All of the tumors demonstrated expression of the E6 and E7 oncogenes, suggesting 
that both the responsive and recurrent tumors are HPV-driven, and the virus is not an 
incidental passenger to an alternate carcinogenic mechanism. Four of the five tumors in 
each group (responsive and recurrent) exhibited the alternate E6*I as the most abundant 
E6 transcript; the full-length E6 transcript was highest in one tumor from each group. Each 





The E6 oncoprotein is translated from the full length E6-E7 transcript, and E7 is translated 
from the E6*I-E7 transcript11-16. This suggests that the tumors with more abundant full 
length E6 transcripts would have higher levels of the E6 oncoprotein, while the tumors 
with more abundant E6*I transcripts would produce higher levels of the E7 oncoprotein.   
All of the tumors evaluated exhibited HPV16 integration into the cellular genome.  
In each of the responsive tumors, at least one viral integration event was identified in 
intragenic regions known to be chromosome fragile sites (2p16, 7p22, and 4p16 in tumors 
1733, 1971, and 2148) or into intragenic regions that were found in multiple tumors 
(16q11.2 and 10p11.1 in tumors 1769 and 1804). This result suggests that these 
integrations may not be entirely random; viral integration is likely occurring into regions in 
the cellular genome that are already unstable, or into regions that share some amount of 
sequence homology with the virus.  We postulate that the intergenic viral integrations seen 
in both the responsive and recurrent tumors contribute to the primary mechanism of HPV-
driven carcinogenesis through disruption of the E6 and E7 transcriptional repressor E2. 
Viral integration into chromosome fragile sites occurs in cervical cancer21-26, resulting in 
disruption of E2 and enhanced expression of E6 and E733,34,54,55.   
The integration analysis of the recurrent tumors revealed viral integrations into 
celluar genes in each case.   This supports our hypothesis that alterations in cellular genes 
as a consequence of viral integration may provide a second mechanism of oncogenesis in 
HNSCC.  Cellular gene disruption caused by viral integration has been reported in rare 
cases of malignant transformation by low-risk HPV types that lack E6 and E7 oncogenic 
activity56-59.   We postulate that hrHPV-induced cancers are driven by sustained activity of 





disruption of the transcriptional repressor E2. We suspect that in most cases integration 
occurs into intragenic regions, and may be random, occur at cellular chromosome fragile 
sites,  or occur in sites with sequence or structural characteristics that favor integration.  
We propose that viral integration events into genic regions alter cellular gene expression 
and mediate additional carcinogenic mechanisms, resulting in a more aggressive tumor 
phenotype. Not only was integration into a cellular gene identified in every recurrent 
tumor, each of the genes disrupted by viral integration (TNFRSF13B, UBE2V2, SCN2A, 
SH2B1, SMOC1, NFIA, and SEMA6D) is involved in a pathway or mechanism that is related to 
cancer, or is differentially expressed in some cancers34-46.  
Transcription analysis of these events indicates that viral integration does not 
necessarily eliminate cellular expression. In the five recurrent tumors, there were seven 
integration events into cellular genes.  In three of the seven events (TNFRSF13B, UBE2V2, 
and SH2B), intact transcripts were detected both across the integration site and elsewhere 
in the gene. In all of these cases, the integration was intronic, and it is possible that the gene 
was spliced in-frame across the integration, eliminating the virus. A second possibility in 
these cases is generation of transcripts from additional copies of the gene that are 
unaffected by the virus.  It is important to note that while intact UBE2V2 transcripts were 
identified both across the integration site and elsewhere in the gene, a fusion transcript 
between HPVE1 and UEB2V2 was generated.  Sequence analysis of this fusion transcript 
demonstrates the severity of chromosome disorder in the tumor cellular genome, as well as 
within the viral genome, with rearrangements resulting in production of a transcript 
containing exon 1 of UBE2V2 (located on chromosome 8), HPV E1, nonsense sequence, HPV 





In the remaining four recurrent tumor integrations (SCN2A, SMOC1, NFIA, and 
SEMA6D), some or all gene transcription was disrupted by viral integration.  In two of these 
cases, genomic instability is again demonstrated by chromosome rearrangements.  In 
tumor 0843, a transcript spanning the integration site in SCN2A was found to involve 
HPVL1, a portion of chromosome 2q34 (including part of the ABCA12 gene), and an 
intergenic region of chromosome 1q32. In tumor 2049, a fusion transcript generated 
between HPV E1 and SMOC1 included both exon 1 of SMOC1 (located on chromosome 14) 
as well as a region of chromosome 3p23.  
Viral integration into a gene does not inevitably cause loss of gene expression; we 
have shown that transcription of some or all of the gene can persist, possibly from 
additional, unaltered copies of the gene, or by splice removal of intron-integrated virus. 
Likewise, detection of gene transcripts does not definitively result in appropriate protein 
production. We cannot eliminate the possibility that the gene transcripts that were found 
were incomplete, inactive, or otherwise defective. An analysis of the full transcript would 
provide a better understanding of the effect of viral integration on the gene. 
  Upregulation of cellular genes is a possible consequence of viral integration as well, 
either through disruption of transcriptional repression, generation of fusion transcripts, or 
other mechanisms. Viral integration can both result from genomic instability and 
contribute to genomic instability. Oncogenic activities of E6 and E7 promote instability 
through unregulated cellular proliferation and alteration in cellular activities, thus 
providing access for integration, and viral integration results in increased viral oncoprotein 
expression (through disruption of E2) and can cause further chromosomal damage60-65.   





breaks, resulting in further rearrangement of the viral and cellular genomes.  As tumor cells 
progressively acquire chromosome rearrangements from oncogenic processes, the genome 
becomes more disorganized and aberrant63,64,66-68.   
The limitations of the DIPS-PCR method restrict detection of cellular integration 
sites to those that have a Taqα1 restriction site in relatively close proximity, and the 
method assumes intact viral and cellular genomes.  Viral rearrangement or convoluted 
integrations (multiple concatenated copies, alternate orientations) can reduce the 
sensitivity of the method and increase the complexity of analyzing the results.  
Identification of cellular genes affected by viral integration in all five recurrent tumors, 
together with detection of rearranged chromosomes, demonstrates the extent of cellular 
disorder present in the recurrent tumor cells.  
Our evaluation of hrHPV transcriptional activity and integration in these tumors 
provides support to our hypothesis that viral integration analysis may be significant in 
distinguishing responsive tumors from those that require additional or alternate therapies.  
Locating cellular genes with viral integration, and assessing subsequent alterations in 
cellular expression may be a significant factor in predicting which tumors will respond to 
current or reduced-intensity treatments, and also possibly in discovering new treatment 









1. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and 
neck cancers. J Clin Oncol. Jun 10 2006;24(17):2606-2611. 
2. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and 
smoking as indicators of response to therapy and survival in oropharyngeal cancer. J 
Clin Oncol. Jul 1 2008;26(19):3128-3137. 
3. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive 
advanced oropharynx cancer patients related to increased risk of distant metastases 
and tumor recurrence. Clin Cancer Res. Feb 15 2010;16(4):1226-1235. 
4. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ 
preservation in advanced oropharynx cancer: response and survival positively 
associated with HPV16 copy number. J Clin Oncol. Jul 1 2008;26(19):3138-3146. 
5. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients 
with oropharyngeal cancer. N Engl J Med. Jul 1 2010;363(1):24-35. 
6. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in 
oropharyngeal cancer are associated with biomarkers including human 
papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat 
Oncol Biol Phys. 2007;69(2 Suppl):S109-111. 
7. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts 
favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. Sep 10 
2003;106(4):553-558. 
8. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in 
relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 
Oct 15 2007;121(8):1813-1820. 
9. Schlecht NF. Prognostic value of human papillomavirus in the survival of head and 
neck cancer patients: an overview of the evidence. Oncol Rep. Nov 2005;14(5):1239-
1247. 
10. Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and 





11. Zheng ZM, Tao M, Yamanegi K, Bodaghi S, Xiao W. Splicing of a cap-proximal human 
Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by 
distance of the intron from its RNA 5' cap. J Mol Biol. Apr 9 2004;337(5):1091-1108. 
12. Tang S, Tao M, McCoy JP, Jr., Zheng ZM. The E7 oncoprotein is translated from 
spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-
positive cervical cancer cell lines via translation reinitiation. J Virol. May 
2006;80(9):4249-4263. 
13. Belaguli NS, Pater MM, Pater A. Splice sites of human papillomavirus type 16 E6 
gene or heterologous gene required for transformation by E7 and accumulation of 
E7 RNA. J Med Virol. Dec 1995;47(4):445-453. 
14. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-
dependent up-regulation of the human papillomavirus E7 gene reactivates cellular 
DNA replication in suprabasal differentiated keratinocytes. Genes & development. 
Oct 1 1995;9(19):2335-2349. 
15. Remm M, Remm A, Ustav M. Human papillomavirus type 18 E1 protein is translated 
from polycistronic mRNA by a discontinuous scanning mechanism. J Virol. Apr 
1999;73(4):3062-3070. 
16. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, Arrand JR. Translation 
of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is 
independent of splicing events within the E6 open reading frame. J Virol. Nov 
1995;69(11):7023-7031. 
17. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is 
frequently found in cervical cancer precursors as demonstrated by a novel 
quantitative real-time PCR technique. J Clin Microbiol. Mar 2002;40(3):886-891. 
18. Cricca M, Morselli-Labate AM, Venturoli S, et al. Viral DNA load, physical status and 
E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical 
lesions. Gynecol Oncol. Sep 2007;106(3):549-557. 
19. Ho CM, Lee BH, Chang SF, et al. Integration of human papillomavirus correlates with 
high levels of viral oncogene transcripts in cervical carcinogenesis. Virus Res. Nov 
2011;161(2):124-130. 
20. Li W, Wang W, Si M, et al. The physical state of HPV16 infection and its clinical 
significance in cancer precursor lesion and cervical carcinoma. J Cancer Res Clin 





21. Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a 
head and neck cancer cell line. Int J Cancer. Jul 10 2004;110(5):701-709. 
22. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of 
genomic integration sites of human papillomavirus genomes in epithelial dysplasia 
and invasive cancer of the female lower genital tract. Cancer Res. Jun 1 
2004;64(11):3878-3884. 
23. Luft F, Klaes R, Nees M, et al. Detection of integrated papillomavirus sequences by 
ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer 
cells. Int J Cancer. Apr 1 2001;92(1):9-17. 
24. Schmitz M, Driesch C, Jansen L, Runnebaum IB, Durst M. Non-random integration of 
the HPV genome in cervical cancer. PLoS One. 2012;7(6):e39632. 
25. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M. Identification of human 
papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. 
Gynecol Oncol. Apr 2009;113(1):120-127. 
26. Klimov E, Vinokourova S, Moisjak E, et al. Human papilloma viruses and cervical 
tumours: mapping of integration sites and analysis of adjacent cellular sequences. 
BMC Cancer. Oct 13 2002;2:24. 
27. Lace MJ, Anson JR, Klussmann JP, et al. Human papillomavirus type 16 (HPV-16) 
genomes integrated in head and neck cancers and in HPV-16-immortalized human 
keratinocyte clones express chimeric virus-cell mRNAs similar to those found in 
cervical cancers. J Virol. Feb 2011;85(4):1645-1654. 
28. Yang H, Yang K, Khafagi A, et al. Sensitive detection of human papillomavirus in 
cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl 
Acad Sci U S A. May 24 2005;102(21):7683-7688. 
29. Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative 
nasopharyngeal carcinoma in white North Americans. Head Neck. May 
2010;32(5):562-567. 
30. Tang AL, Hauff SJ, Owen JH, et al. UM-SCC-104: a new human papillomavirus-16-
positive cancer stem cell-containing head and neck squamous cell carcinoma cell 





31. Walline HM, Komarck CM, McHugh JB, et al. High-risk human papillomavirus 
detection in oropharyngeal, nasopharyngeal, and, oral cavity cancers: Comparison of 
multiple methods. JAMA Otolaryngology. In Press 2013. 
32. Durkin SG, Glover TW. Chromosome fragile sites. Annual review of genetics. 
2007;41:169-192. 
33. Pozzi S, Zambelli F, Merico D, et al. Transcriptional network of p63 in human 
keratinocytes. PLoS One. 2009;4(3):e5008. 
34. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor 
superfamily in B-cell biology and disease. Immunological reviews. Nov 
2011;244(1):115-133. 
35. Li M, Xiong ZG. Ion channels as targets for cancer therapy. International journal of 
physiology, pathophysiology and pharmacology. 2011;3(2):156-166. 
36. Roger S, Potier M, Vandier C, Besson P, Le Guennec JY. Voltage-gated sodium 
channels: new targets in cancer therapy? Current pharmaceutical design. 
2006;12(28):3681-3695. 
37. Le Guennec JY, Ouadid-Ahidouch H, Soriani O, Besson P, Ahidouch A, Vandier C. 
Voltage-gated ion channels, new targets in anti-cancer research. Recent patents on 
anti-cancer drug discovery. Nov 2007;2(3):189-202. 
38. Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA. Voltage-sensitive ion channels 
and cancer. Cancer metastasis reviews. Sep 2006;25(3):493-500. 
39. Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress 
constitutive kappa interferon transcription via E6 to prevent pathogen recognition 
receptor and antiviral-gene expression. J Virol. Nov 2011;85(21):11372-11380. 
40. Cheng L, Wang P, Yang S, et al. Identification of genes with a correlation between 
copy number and expression in gastric cancer. BMC medical genomics. 2012;5:14. 
41. Santarpia L, Iwamoto T, Di Leo A, et al. DNA Repair Gene Patterns as Prognostic and 
Predictive Factors in Molecular Breast Cancer Subtypes. The oncologist. Sep 26 2013. 
42. Brellier F, Ruggiero S, Zwolanek D, et al. SMOC1 is a tenascin-C interacting protein 
over-expressed in brain tumors. Matrix biology : journal of the International Society 





43. Micci F, Thorsen J, Panagopoulos I, et al. High-throughput sequencing identifies an 
NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). 
Leukemia. Apr 2013;27(4):980-982. 
44. Toyofuku T, Zhang H, Kumanogoh A, et al. Dual roles of Sema6D in cardiac 
morphogenesis through region-specific association of its receptor, Plexin-A1, with 
off-track and vascular endothelial growth factor receptor type 2. Genes & 
development. Feb 15 2004;18(4):435-447. 
45. Gu C, Giraudo E. The role of semaphorins and their receptors in vascular 
development and cancer. Experimental cell research. May 15 2013;319(9):1306-
1316. 
46. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A. The plexin-A1 receptor 
activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB 
to mediate survival and anchorage-independent growth of malignant mesothelioma 
cells. Cancer Res. Feb 15 2009;69(4):1485-1493. 
47. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends 
in the U.S. population ages 20-44 years. Cancer. May 1 2005;103(9):1843-1849. 
48. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between 
human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. May 
3 2000;92(9):709-720. 
49. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer 
and the role of oncogenic human papilloma virus. Laryngoscope. Dec 
2007;117(12):2115-2128. 
50. Gillison ML, Castellsague X, Chaturvedi A, et al. Comparative epidemiology of HPV 
infection and associated cancers of the head and neck and cervix. Int J Cancer. Apr 9 
2013. 
51. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human 
papillomavirus-positive head and neck squamous cell carcinoma in a prospective 
clinical trial. J Natl Cancer Inst. Feb 20 2008;100(4):261-269. 
52. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human 
papillomavirus type 16-positive and human papillomavirus type 16-negative head 





53. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally 
advanced head and neck cancer: 5-year survival data from a phase 3 randomised 
trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. Jan 
2010;11(1):21-28. 
54. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of 
human papillomavirus type 16 increases viral immortalization capacity. Proc Natl 
Acad Sci U S A. Apr 1 1992;89(7):3159-3163. 
55. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G. Human 
papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical 
neoplasia. Mol Diagn. 2004;8(1):57-64. 
56. Huebbers CU, Preuss SF, Kolligs J, et al. Integration of HPV6 and downregulation of 
AKR1C3 expression mark malignant transformation in a patient with juvenile-onset 
laryngeal papillomatosis. PLoS One. 2013;8(2):e57207. 
57. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: 
infection with high-risk vs low-risk human papillomaviruses. APMIS : acta 
pathologica, microbiologica, et immunologica Scandinavica. Jun 2010;118(6-7):471-
493. 
58. Reidy PM, Dedo HH, Rabah R, et al. Integration of human papillomavirus type 11 in 
recurrent respiratory papilloma-associated cancer. Laryngoscope. Nov 
2004;114(11):1906-1909. 
59. Kahn T, Turazza E, Ojeda R, et al. Integration of human papillomavirus type 6a DNA 
in a tonsillar carcinoma: chromosomal localization and nucleotide sequence of the 
genomic target region. Cancer Res. Mar 1 1994;54(5):1305-1312. 
60. Pett MR, Alazawi WO, Roberts I, et al. Acquisition of high-level chromosomal 
instability is associated with integration of human papillomavirus type 16 in 
cervical keratinocytes. Cancer Res. Feb 15 2004;64(4):1359-1368. 
61. Gagne SE, Jensen R, Polvi A, et al. High-resolution analysis of genomic alterations 
and human papillomavirus integration in anal intraepithelial neoplasia. Journal of 
acquired immune deficiency syndromes. Oct 1 2005;40(2):182-189. 
62. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. 
DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes 
in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. 





63. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins 
independently induce numerical and structural chromosome instability. Cancer Res. 
Dec 1 2002;62(23):7075-7082. 
64. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: 
modeling the origins of genomic instability. Oncogene. Sep 9 2002;21(40):6241-
6248. 
65. Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: 
lessons learned from human papillomaviruses. Cancer Lett. Jun 28 
2011;305(2):113-122. 
66. Boccardo E. HPV-mediated genome instability: at the roots of cervical 
carcinogenesis. Cytogenetic and genome research. 2010;128(1-3):57-65. 
67. Thomas LK, Bermejo JL, Vinokurova S, et al. Chromosomal gains and losses in 
human papillomavirus-associated neoplasia of the lower genital tract - A systematic 
review and meta-analysis. Eur J Cancer. Sep 17 2013. 
68. Huang FY, Kwok YK, Lau ET, Tang MH, Ng TY, Ngan HY. Genetic abnormalities and 












Discussion and Summary 
 
Introduction 
 The involvement of high-risk human papillomavirus in cervical carcinogenesis has 
been well-studied; screening, detection of early lesions, HPV testing, and colposcopy have 
been largely successful in reducing the incidence of cervical cancer1,2.  An estimated 42% of 
women in the United States harbor cervical HPV; the worldwide annual incidence of 
cervical cancer is 530,000 and approximately half of these cases result in death3. High-risk 
HPV is the causative agent in nearly all cervical cancers, 71% of these are attributable to 
HPV16 or HPV184,5.  Additional HPV factors associated with increased risk in cervical 
cancer include infection with multiple hrHPV types, transcriptionally active viral 
oncogenes, and viral integration6,7.  Non-HPV cofactors associated with cervical 
carcinogenesis and progression include smoking, co-infection with additional sexually 
transmitted diseases, and hormonal contraceptive use6.  
The rate of oral HPV infection is lower than that of cervical HPV infection, 
approximately 7% for adults in the United States. The worldwide incidence of head and 
neck squamous cell carcinoma (HNSCC) is 550,000, and 55% of these cases result in death3.  
Depending on tumor site, the proportion of HPV-positive HNSCC is between 10% and 80%, 
the highest occurring in OPSCC (83% in our study)8.  As the incidence of cervical cancer is 
decreasing, head and neck cancers are increasing, due to the substantial rise in HPV-
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induced oropharyngeal tumors.  Tobacco and alcohol have historically been the strongest 
etiologic factors in HNSCC, but hrHPV is now recognized as the primary etiologic factor in 
oropharynx cancer9-17. This change in epidemiology is attributed to increased sexual 
activity involving multiple partners and HPV transmission between oral and anogenital 
regions. The characteristics shared by these locations make them appropriate 
environments for HPV infection, including thin mucosal epithelium or transition from 
squamous to columnar epithelium, an increased probability for inflammation from 
concurrent infection and trauma, or microabrasions facilitating viral access to basal cells 
for infection.  
In contrast to cervical cancer, screening and early detection is lacking in HNSCC. The 
majority of patients with HPV-related oropharyngeal cancer present with advanced stage 
disease due to early dissemination to regional lymph node, and primary tumors are small 
and often located in inaccessible regions15,18-25.  Nevertheless, response to therapy and 
survival is dramatically better in patients with HPV-positive tumors than in those with 
HPV-negative oropharynx cancer10,13,15,16,26-32, prompting wide interest in reduction of 
treatment intensity for these patients33,34. However, there is a minority of HPV-positive 
oropharyngeal tumors that fail to respond to treatment, and patients with these tumors 
have local recurrences or distant metastasis35.  Identification and characterization of 
factors that could be used to classify HPV-positive tumors into appropriate treatment 
groups would allow patients with responsive tumors to receive less intense treatments 
than those currently used. This type of reduction in treatment intensity could prevent 
treatment related morbidities such as post-radiation loss of salivary flow, swallowing 
difficulty, osteoradionecrosis, and chemotherapy-induced neuropathies33.   Likewise, if 
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potentially non-responsive tumors could be recognized at the time of diagnosis, further 
evaluation could be performed to identify potential targets for effective personalized 
therapy that could increase likelihood of successful treatment.   
 
Summary of Chapters 
 In Chapter II, hrHPV detection by three methods was assessed in oropharyngeal, 
oral cavity and nasopharyngeal tumors.  p16INK4a immunohistochemistry, HPV in situ 
hybridization, and HPV PCR-MassArray were compared, using L1 consensus PCR and 
sequencing as the definitive assay for resolution of discordant test results. Among the 
oropharyngeal tumors evaluated, 83% were HPV-positive, and of these 94% were HPV-16. 
In the nasopharyngeal tumors, 44% were positive for HPV with a more equivalent 
distribution among the 4 types detected: HPV16 (37.5%), HPV18 (25%), HPV39 (12.5%) 
and HPV59 (25%). Only 10% of the oral cavity tumors were HPV-positive, 40% of these 
were HPV16, and the remaining 60% consisted of other high-risk types or dual hrHPV 
infections.  
HPV-positive oropharynx cancers have a better prognosis than HPV-positive oral 
cavity or nasopharynx tumors, in which HPV has been associated with worse outcome36,37 
(unpublished data, Stemark et al., 2013).  Oropharyngeal tumors arising in lymphoid tissue 
of the tonsils may be inherently easier to treat based on their proximity to lymphocytes and 
likely generation of an immune response to viral antigens. However, it is possible that the 
non-responsive HPV-positive tumors that constitute the minority subset share viral 
characteristics with HPV-positive tumors at the other HNSCC sites. We have not performed 
viral copy number, HPV transcription, or integration analysis on tumors other than OPSCC 
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or in HPV types other than HPV16.  It would be interesting to investigate these factors to 
determine whether they are similar or significantly different from HPV16 in oropharynx 
tumors.  
When HPV detection methods were compared, PCR-MassArray had 99.5% 
sensitivity and 100% specificity, p16 immunohistochemistry had 94.2% sensitivity and 
85.5% specificity, and HPV in situ hybridization had 82.9% sensitivity and 81% specificity.  
The correlation between p16-positive and HPV-positive results suggests that the virus is 
transcriptionally active and contributing to carcinogenesis in these tumors.  The discordant 
cases negative for p16 expression and positive for HPV by PCR-MassArray may represent 
tumors with inactive HPV, or disruption of p16 expression due to mutation, deletion, or 
methylation affecting the CDKN2A locus that encodes p16.  The discordant cases positive 
for p16 expression and negative for HPV by PCR-MassArray may include tumors that are 
negative for HPV but have another mechanism for upregulation of p16, such as tumors 
induced by a type of hrHPV not represented in the genotyping assay, or tumors with viral 
rearrangement or nucleotide polymorphism in the region of E6 that is assessed in the 
assay.  Consensus PCR and sequencing is a time- and resource-heavy method, but is a 
valuable tool for resolving discordant cases.  L1 consensus primers should detect any 
known HPV type present in a sample, including those with E6 rearrangements that are 
false-negative by PCR-MassArray and rare HPV types or variants, which can subsequently 
be identified by sequencing the L1 consensus PCR product.   While this study demonstrates 
that PCR-MassArray is the most accurate and informative test, it is important to include 
p16 expression as an indicator of viral activity. Viral DNA may be detected in latent or 
147 
 
inactive infections, and it is essential to identify tumors in which HPV is active and driving 
carcinogenesis in order to use HPV status as a predictive factor in HNSCC.   
In chapter III, we examined viral copy number, early transcripts, and viral 
integration in all seven known HPV-positive cell lines from HNSCC, representing tumors 
that failed to respond to therapy.  All seven of the cell lines were positive for HPV16 and no 
other hrHPV types were detected in the cell lines when tested in our PCR-MassArray assay 
for 15 high-risk types.  Each cell line demonstrated HPV E6-E7 viral oncogene expression, 
with dominant expression of the E6*I-E7 alternate transcript, indicating active viral 
oncogene expression.   HPV16 was integrated in each of the cell lines evaluated, and 
integration occurred into cellular genes TP63, DCC, JAK1, TERT, ATR, ETV6, PGR, PTPRN2, 
and TMEM237.  Remarkably, each of these genes is associated with cancer pathways or 
differential expression in one or more cancers. The integration events were confirmed by 
direct PCR and sequencing of the viral-cellular fusions, eliminating false-positive results 
that could have been artifacts induced by the DIPS-PCR method.  Transcript analysis of the 
integration events evaluated HPV-cellular fusion transcripts, cellular exon-exon transcripts 
spanning the integration site, and exon-exon or within-exon transcripts outside the region 
involved in the integration.  Our results indicate that DCC is disrupted in UM-SCC-104 and 
PGR is disrupted in UPCI:SCC154, since no transcripts for either of these genes were 
produced. However, our analysis does not prove that this loss is definitively caused by HPV 
integration into these genes.  Our analysis revealed one HPV-cellular fusion transcript, 
which occurred in UM-SCC-47 between HPV E2 and TP63, and was out of frame.  One or 
more transcripts were produced for the remaining integration events in the cell lines, but 
were not consistent within each gene for each event.  In UPCI:SCC152, the ATR transcript 
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upstream of the integration event was generated, but the transcript spanning the 
integration site was not in-frame, and the transcript downstream from the integration site 
was not produced at all. Similarly, in UPCI:SCC90 the transcript spanning the integration 
site was not produced, but the transcript downstream from the integration site was 
generated.  Disruption of a cellular gene due to viral integration may or may not determine 
knockout of the gene, depending on whether the second copy (or multiple copies, in the 
case of aneuploid tumor cells) is affected. The affected cellular gene may be upregulated, 
disrupted, or unaffected, contingent on strand orientation, as well as the precise viral-
cellular junction relative to sequence elements such as promoters and splice sites.   
Our assessment of cellular transcripts affected by viral integration provides 
important but limited information on the consequence of HPV integration on cellular gene 
expression.  A more comprehensive analysis of cellular gene transcripts and resulting 
protein expression would provide improved understanding of the effects of viral 
integration into cellular genes, and how resulting changes in cellular activity contribute to 
tumor response.  
We postulate that while integration into gene poor or chromosome fragile sites 
occurs in the majority of HPV-driven cancers, secondary integration events into cellular 
genes, specifically tumor suppressor genes or those involved in cancer pathways may 
separate responsive tumors from those with more aggressive malignant behavior.  In our 
model for differentiation of responsive and non-responsive HPV-positive head and neck 
tumors, early responsive tumors are driven by sustained E6 and E7 oncoprotein activity 
(associated with intergenic or fragile site viral integration, loss of E2 transcriptional 
repression, and E6*I alternate transcripts) alone, while more advanced tumors that will fail 
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to respond to treatment have viral integration into cellular genes, which alters cellular 
expression or activity and provides additional carcinogenic drivers.  We will continue to 
investigate the hypothesis to determine if supporting or refuting evidence can be generated 
from the study of more tumors from patients whose outcome is known. 
 In chapter IV, responsive and recurrent tumors from patients whose treatment is 
known, were evaluated for viral copy number, early transcripts, and viral integration. The 
average HPV16 copies/cell for the responsive tumors was 242.8, more than twice the 
average HPV16 copy number for both the recurrent tumors (average value of 92.6) and the 
HPV16-positive cell lines evaluated in Chapter III (average value of 100.6).  This 
observation, while not significant due to small sample size, is concordant with our 
hypothesis that earlier, responsive tumors often contain many episomal HPV copies, but 
that more advanced cancers lose episomal copies with fewer copies of HPV which are 
mostly integrated in the cellular genome. 
 All of the tumors we evaluated demonstrated active viral transcription. The majority 
of tumors in each group (4/5 in the responsive and 5/5 in the recurrent tumors) expressed 
E6*I as the most abundant transcript, suggesting that E7 is the primary translated 
oncoprotein in these tumors.  One recurrent and one responsive tumor expressed full 
length E6 as the most abundant transcript, suggesting that E6 is the dominant oncoprotein 
translated in these tumors38-43. Relative levels of viral transcripts and oncoprotein 
translation may be associated with different tumor characteristics, but our limited sample 
size and comparative equivalence between responsive and recurrent tumors prevents this 
analysis in our study. 
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Viral integration into intergenic chromosome sites was found in each of the 
responsive tumors evaluated, whereas HPV integration into a cancer-related cellular gene 
was found in only one responsive tumor.  The integration events were confirmed by direct 
PCR and sequencing of the viral-cellular fusions, eliminating false-positive results that 
could have been artifacts induced by the DIPS-PCR method. The intergenic sites of viral 
integration included three known chromosome fragile sites and two chromosome sites that 
were involved in multiple integration events, suggesting that these integrations may not be 
entirely random. We suspect that HPV integrates into regions in the cellular genome that 
are unstable or into regions that share some amount of sequence homology with the 
virus44.  This supports our hypothesis that intergenic viral integration seen in both 
responsive and recurrent tumors contributes to the primary mechanism of HPV-driven 
carcinogenesis through disruption of E2, the transcriptional repressor of E6 and E7.  Viral 
integration into chromosome fragile sites is similarly seen in most cervical cancers44-49, 
typically resulting in disruption of E2 and enhanced expression of E6 and E733,34,50,51.   
We identified HPV16 integration into cellular genes (TNFRSF13B, UBE2V2, SCN2A, 
SH2B1, SMOC1, NFIA, and SEMA6D) in each of the recurrent tumors.  Each of the cellular 
genes identified is involved in a pathway or mechanism related to cancer, or is 
differentially expressed in one or more cancers52-64.  However, the precise activity of each 
gene haboring an integrated viral segment and how viral integration might alter that 
activity is unknown.  Our analysis indicates that integration into a gene does not inevitably 
result in complete loss of gene expression of the host gene harboring the integrated virus. 
We found that at least partial transcription of some of the cellular gene involved can 
persist, possibly from additional, unaltered copies of the gene, or by splice removal of 
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intron-integrated virus.  In contrast, detection of a transcript does not guarantee quality; it 
conceiveable that gene transcripts are generated but are incomplete, inactive, or otherwise 
ineffective for accurate protein production. Upregulation of cellular genes is an additional 
possible consequence of viral integration, either through disruption of transcriptional 
repression, generation of fusion transcripts, or other mechanisms. 
Our transcript analysis of viral-cellular fusion transcripts, exon-exon cellular 
transcripts spanning the integration sites, and exon-exon or within-exon cellular 
transcripts outside of the integration region demonstrates that effects of viral integration 
on cellular genes is not straightforward.  In four cases (TP63 in responsive tumor 1971, 
TNFRSF13B in recurrent tumor 0732, SH2B in recurrent tumor 1040, and UBE2V2 in 
recurrent tumor 2049) the cellular transcript across the integration site and downstream 
of the integration was generated and spliced in frame.  In other cases, at least one of the 
cellular transcripts was produced, but failed sequence alignment.  In three cases, viral and 
cellular rearrangements were discovered in viral-cellular fusion transcripts or cellular 
transcripts spanning the integration site. In recurrent tumor 0843, a transcript across the 
integration site in SCN2A included HPVL1, a portion of chromosome 2q34 (including part of 
the ABCA12 gene), and an intergenic region of chromosome 1q32.  In tumor 2049, a fusion 
transcript generated between HPV E1 and SMOC1 included exon 1 of SMOC1 (located on 
chromosome 14) as well as a region of chromosome 3p23.  The fusion transcript between 
HPVE1 and UEB2V2 in recurrent tumor 2049 contained exon 1 of UBE2V2 (located on 
chromosome 8), HPV E1, nonsense sequence, HPV L1, and an intergenic region of 
chromosome 17q11.2.  These results demonstrate the severe disorder and instability 
present in the cellular genome as well as the limitations of the DIPS-PCR assay.    
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Oncogenic activities of E6 and E7 promote instability through unregulated cellular 
proliferation and alteration in cellular activities, and viral integration results in increased 
viral oncoprotein expression through disruption of E2.  Increased viral oncogene 
expression inhibits p53 and Rb and can lead to further accumulation of chromosomal 
damage65-70.   The process of HPV integration into the cellular genome may cause additional 
dsDNA breaks, resulting in further rearrangement of the viral and cellular genomes.  In 
cervical cancer, HPV integration has been shown to cause structural alterations in the 
cellular genome at the site of integration, including genomic rearrangements, local 
amplifications, and genomic deletions71,72.  As tumor cells progressively acquire 
chromosome rearrangements from oncogenic processes, the genome becomes more 
disorganized and aberrant68,69,73-75.   
Identification of viral integration into TNFRSF13B, UBE2V2, SCN2A, SH2B1, SMOC1, NFIA, 
and SEMA6D into the recurrent tumors supports our hypothesis that integration into 
cellular genes is a secondary event that could contribute to a more aggressive tumor 
behavior, recurrence, and metastasis by deregulation of cellular genes.  Identification of 
tumors with viral integration into and disruption of cellular genes may be one factor for 
identifying a subset of tumors unlikely to respond to concurrent chemo-RT. Furthermore, 
evaluation of integration-induced alterations in cellular expression may provide evidence 
for new treatment targets.   
 
Future Directions 
 The mechanism for differences in outcome for HPV-positive head and neck cancers 
at different tumor sites is not fully understood. Investigation of viral copy number, HPV 
153 
 
early gene transcription, and integration analysis on HPV-positive oral cavity and 
nasopharynx tumors would allow elucidation of viral activity, physical status, and possible 
alterations in cellular gene expression. It is possible that HPV-positive tumors at non-
oropharynx sites may share characteristics with the subset of non-responsive HPV-positive 
oropharyngeal tumors that allow these tumors to be resistant to current therapies.  
In our transcription and integration studies, we evaluated cell lines and tumors that 
were HPV16-induced, as these were most abundant and readily available. It would be 
interesting to examine tumors and cell lines with non-HPV16 high-risk types to determine 
whether E6 splicing and integration patterns mimic those seen in HPV16.  This may be of 
particular interest in nasopharynx and oral cavity tumors, where we have observed higher 
relative incidence of non-HPV16 high-risk types.  
HPV early gene transcript analysis would perhaps be more meaningful if we knew 
the p53 status and expression in the tumors examined. The E6*I alternate transcript lacks 
several key amino acids in the homodimerization region, required for interaction with 
E6AP and p53; perhaps tumors with more abundant E6*I compared to full length E6 have 
differences in p53 protein stability and activity. 
To better understand the consequences of viral integration into cellular genes, and 
to determine whether this is a useful strategy for tumor categorization, a more 
comprehensive analysis of expression cellular genes affected by integration should be 
performed. This would include evaluation of full transcripts and protein expression.  A 
more thorough exploration of HPV-cellular fusion transcripts may reveal alternate splicing 
from upstream viral open reading frames to cellular exons.  Additionally, examination of 
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the HPV genome distal to the integration site would discern whether the virus has 
integrated into multiple different sites in possibly rearranged chromosomes.  
To determine whether there is an association between alterations in cellular gene 
expression due to HPV integration and increased malignancy, gene knock-in and post-
transcriptional silencing experiments could be performed for the cancer-related genes that 
contained viral integrations. The HOK-16A and HOK-16B cell lines are human oral 
keratinocytes transformed by transfection with recombinant HPV16, and contain 
approximately 40 and approximately 25 copies of integrated HPV16 DNA per cell, 
respectively76.  While HOK-16A and HOK-16B cell lines are immortal, they are not 
tumorigenic, making them ideal models in which to study mechanisms of multistep oral 
carcinogenesis with knock-in and silencing experiments to simulate altered gene 
expression caused by viral integration.  
Resolution of the allelic origin of transcripts from cellular genes involved in viral 
integrations could be approached with allele frequency matching studies; intact transcripts 
may have been generated from the alternate gene copy, and viral integration may not 
change gene expression.  Minor allele frequency studies may also reveal aneuploidy within 
tumor cells, as seen in the UM-SCC-47 cell line where pseudotetraploidy and other 








1. De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F. Detection of 
human papillomavirus type 16 integration in pre-neoplastic cervical lesions and 
confirmation by DIPS-PCR and sequencing. J Clin Virol. Jan 2007;38(1):7-13. 
2. Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M. Diagnosing 
cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer 
Res. Jan 1 2010;70(1):249-256. 
3. Gillison ML, Castellsague X, Chaturvedi A, et al. Comparative epidemiology of HPV 
infection and associated cancers of the head and neck and cervix. Int J Cancer. Apr 9 
2013. 
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in 
cervical cancer: a worldwide perspective. International biological study on cervical 
cancer (IBSCC) Study Group. J Natl Cancer Inst. Jun 7 1995;87(11):796-802. 
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary 
cause of invasive cervical cancer worldwide. J Pathol. Sep 1999;189(1):12-19. 
6. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology 
of human cancer. Vaccine. Aug 31 2006;24 Suppl 3:S3/1-10. 
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human 
papillomavirus types associated with cervical cancer. N Engl J Med. Feb 6 
2003;348(6):518-527. 
8. Walline HM, Komarck CM, McHugh JB, et al. High-risk human papillomavirus 
detection in oropharyngeal, nasopharyngeal, and, oral cavity cancers: Comparison of 
multiple methods. JAMA Otolaryngology. In Press 2013. 
9. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus 
and oropharyngeal cancer. N Engl J Med. May 10 2007;356(19):1944-1956. 
10. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and 
neck cancers. J Clin Oncol. Jun 10 2006;24(17):2606-2611. 
11. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human 
papillomavirus-related and -unrelated oral squamous cell carcinomas in the United 
States. J Clin Oncol. Feb 1 2008;26(4):612-619. 
156 
 
12. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between 
human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. May 
3 2000;92(9):709-720. 
13. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and 
smoking as indicators of response to therapy and survival in oropharyngeal cancer. J 
Clin Oncol. Jul 1 2008;26(19):3128-3137. 
14. Licitra L, Bossi P, Locati LD. A multidisciplinary approach to squamous cell 
carcinomas of the head and neck: what is new? Curr Opin Oncol. May 
2006;18(3):253-257. 
15. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive 
advanced oropharynx cancer patients related to increased risk of distant metastases 
and tumor recurrence. Clin Cancer Res. Feb 15 2010;16(4):1226-1235. 
16. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ 
preservation in advanced oropharynx cancer: response and survival positively 
associated with HPV16 copy number. J Clin Oncol. Jul 1 2008;26(19):3138-3146. 
17. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer 
and the role of oncogenic human papilloma virus. Laryngoscope. Dec 
2007;117(12):2115-2128. 
18. Chenevert J, Seethala RR, Barnes EL, Chiosea SI. Squamous cell carcinoma metastatic 
to neck from an unknown primary: the potential impact of modern pathologic 
evaluation on perceived incidence of human papillomavirus-positive oropharyngeal 
carcinoma prior to 1970. The Laryngoscope. Apr 2012;122(4):793-796. 
19. Desai PC, Jaglal MV, Gopal P, et al. Human papillomavirus in metastatic squamous 
carcinoma from unknown primaries in the head and neck: a retrospective 7 year 
study. Experimental and molecular pathology. Oct 2009;87(2):94-98. 
20. El-Mofty SK, Zhang MQ, Davila RM. Histologic identification of human 
papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a 
reliable predictor of the site of an occult head and neck primary carcinoma. Head 
and neck pathology. Sep 2008;2(3):163-168. 
21. McGovern SL, Williams MD, Weber RS, et al. Three synchronous HPV-associated 
squamous cell carcinomas of Waldeyer's ring: case report and comparison with 
Slaughter's model of field cancerization. Head & neck. Aug 2010;32(8):1118-1124. 
22. Roeser MM, Alon EE, Olsen KD, Moore EJ, Manduch M, Wismayer DJ. Synchronous 
bilateral tonsil squamous cell carcinoma. The Laryngoscope. 2010;120 Suppl 4:S181. 
157 
 
23. Strojan P, Ferlito A, Langendijk JA, et al. Contemporary management of lymph node 
metastases from an unknown primary to the neck: II. a review of therapeutic 
options. Head & neck. Feb 2013;35(2):286-293. 
24. Vent J, Haidle B, Wedemeyer I, et al. p16 Expression in carcinoma of unknown 
primary: Diagnostic indicator and prognostic marker. Head & neck. Jan 23 2013. 
25. Zengel P, Assmann G, Mollenhauer M, et al. Cancer of unknown primary originating 
from oropharyngeal carcinomas are strongly correlated to HPV positivity. Virchows 
Archiv : an international journal of pathology. Sep 2012;461(3):283-290. 
26. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients 
with oropharyngeal cancer. N Engl J Med. Jul 1 2010;363(1):24-35. 
27. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human 
papillomavirus-positive head and neck squamous cell carcinoma in a prospective 
clinical trial. J Natl Cancer Inst. Feb 20 2008;100(4):261-269. 
28. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in 
oropharyngeal cancer are associated with biomarkers including human 
papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat 
Oncol Biol Phys. 2007;69(2 Suppl):S109-111. 
29. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts 
favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. Sep 10 
2003;106(4):553-558. 
30. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in 
relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 
Oct 15 2007;121(8):1813-1820. 
31. Schlecht NF. Prognostic value of human papillomavirus in the survival of head and 
neck cancer patients: an overview of the evidence. Oncol Rep. Nov 2005;14(5):1239-
1247. 
32. Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and 
survival in head and neck cancer. Oral Oncol. Feb 2008;44(2):133-142. 
33. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming 
to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional 
results. J Clin Oncol. Jun 1 2010;28(16):2732-2738. 
158 
 
34. Hoffmann TK, Sonkoly E, Hauser U, et al. Alterations in the p53 pathway and their 
association with radio- and chemosensitivity in head and neck squamous cell 
carcinoma. Oral Oncol. Dec 2008;44(12):1100-1109. 
35. Spector ME, Gallagher KK, Light E, et al. Matted nodes: Poor prognostic marker in 
oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head 
Neck. Jan 13 2012. 
36. Duray A, Descamps G, Decaestecker C, et al. Human papillomavirus DNA strongly 
correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope. Jul 
2012;122(7):1558-1565. 
37. Lee LA, Huang CG, Liao CT, et al. Human papillomavirus-16 infection in advanced 
oral cavity cancer patients is related to an increased risk of distant metastases and 
poor survival. PLoS One. 2012;7(7):e40767. 
38. Zheng ZM, Tao M, Yamanegi K, Bodaghi S, Xiao W. Splicing of a cap-proximal human 
Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by 
distance of the intron from its RNA 5' cap. J Mol Biol. Apr 9 2004;337(5):1091-1108. 
39. Tang S, Tao M, McCoy JP, Jr., Zheng ZM. The E7 oncoprotein is translated from 
spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-
positive cervical cancer cell lines via translation reinitiation. Journal of virology. May 
2006;80(9):4249-4263. 
40. Belaguli NS, Pater MM, Pater A. Splice sites of human papillomavirus type 16 E6 
gene or heterologous gene required for transformation by E7 and accumulation of 
E7 RNA. J Med Virol. Dec 1995;47(4):445-453. 
41. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-
dependent up-regulation of the human papillomavirus E7 gene reactivates cellular 
DNA replication in suprabasal differentiated keratinocytes. Genes Dev. Oct 1 
1995;9(19):2335-2349. 
42. Remm M, Remm A, Ustav M. Human papillomavirus type 18 E1 protein is translated 
from polycistronic mRNA by a discontinuous scanning mechanism. Journal of 
virology. Apr 1999;73(4):3062-3070. 
43. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, Arrand JR. Translation 
of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is 




44. Schmitz M, Driesch C, Jansen L, Runnebaum IB, Durst M. Non-random integration of 
the HPV genome in cervical cancer. PLoS One. 2012;7(6):e39632. 
45. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of 
genomic integration sites of human papillomavirus genomes in epithelial dysplasia 
and invasive cancer of the female lower genital tract. Cancer Res. Jun 1 
2004;64(11):3878-3884. 
46. Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a 
head and neck cancer cell line. Int J Cancer. Jul 10 2004;110(5):701-709. 
47. Luft F, Klaes R, Nees M, et al. Detection of integrated papillomavirus sequences by 
ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer 
cells. Int J Cancer. Apr 1 2001;92(1):9-17. 
48. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M. Identification of human 
papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. 
Gynecol Oncol. Apr 2009;113(1):120-127. 
49. Klimov E, Vinokourova S, Moisjak E, et al. Human papilloma viruses and cervical 
tumours: mapping of integration sites and analysis of adjacent cellular sequences. 
BMC Cancer. Oct 13 2002;2:24. 
50. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of 
human papillomavirus type 16 increases viral immortalization capacity. Proc Natl 
Acad Sci U S A. Apr 1 1992;89(7):3159-3163. 
51. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G. Human 
papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical 
neoplasia. Mol Diagn. 2004;8(1):57-64. 
52. Roger S, Potier M, Vandier C, Besson P, Le Guennec JY. Voltage-gated sodium 
channels: new targets in cancer therapy? Curr Pharm Des. 2006;12(28):3681-3695. 
53. Li M, Xiong ZG. Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol 
Pharmacol. 2011;3(2):156-166. 
54. Le Guennec JY, Ouadid-Ahidouch H, Soriani O, Besson P, Ahidouch A, Vandier C. 
Voltage-gated ion channels, new targets in anti-cancer research. Recent Pat 
Anticancer Drug Discov. Nov 2007;2(3):189-202. 
55. Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA. Voltage-sensitive ion channels 
and cancer. Cancer Metastasis Rev. Sep 2006;25(3):493-500. 
160 
 
56. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor 
superfamily in B-cell biology and disease. Immunol Rev. Nov 2011;244(1):115-133. 
57. Cheng L, Wang P, Yang S, et al. Identification of genes with a correlation between 
copy number and expression in gastric cancer. BMC Med Genomics. 2012;5:14. 
58. Santarpia L, Iwamoto T, Di Leo A, et al. DNA Repair Gene Patterns as Prognostic and 
Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist. Sep 26 2013. 
59. Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress 
constitutive kappa interferon transcription via E6 to prevent pathogen recognition 
receptor and antiviral-gene expression. J Virol. Nov 2011;85(21):11372-11380. 
60. Brellier F, Ruggiero S, Zwolanek D, et al. SMOC1 is a tenascin-C interacting protein 
over-expressed in brain tumors. Matrix Biol. Apr 2011;30(3):225-233. 
61. Micci F, Thorsen J, Panagopoulos I, et al. High-throughput sequencing identifies an 
NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). 
Leukemia. Apr 2013;27(4):980-982. 
62. Gu C, Giraudo E. The role of semaphorins and their receptors in vascular 
development and cancer. Exp Cell Res. May 15 2013;319(9):1306-1316. 
63. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A. The plexin-A1 receptor 
activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB 
to mediate survival and anchorage-independent growth of malignant mesothelioma 
cells. Cancer Res. Feb 15 2009;69(4):1485-1493. 
64. Toyofuku T, Zhang H, Kumanogoh A, et al. Dual roles of Sema6D in cardiac 
morphogenesis through region-specific association of its receptor, Plexin-A1, with 
off-track and vascular endothelial growth factor receptor type 2. Genes Dev. Feb 15 
2004;18(4):435-447. 
65. Pett MR, Alazawi WO, Roberts I, et al. Acquisition of high-level chromosomal 
instability is associated with integration of human papillomavirus type 16 in 
cervical keratinocytes. Cancer Res. Feb 15 2004;64(4):1359-1368. 
66. Gagne SE, Jensen R, Polvi A, et al. High-resolution analysis of genomic alterations 
and human papillomavirus integration in anal intraepithelial neoplasia. J Acquir 
Immune Defic Syndr. Oct 1 2005;40(2):182-189. 
67. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. 
DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes 
161 
 
in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. 
Clin Cancer Res. May 1 2004;10(9):3059-3063. 
68. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins 
independently induce numerical and structural chromosome instability. Cancer Res. 
Dec 1 2002;62(23):7075-7082. 
69. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: 
modeling the origins of genomic instability. Oncogene. Sep 9 2002;21(40):6241-
6248. 
70. Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: 
lessons learned from human papillomaviruses. Cancer Lett. Jun 28 
2011;305(2):113-122. 
71. Peter M, Stransky N, Couturier J, et al. Frequent genomic structural alterations at 
HPV insertion sites in cervical carcinoma. J Pathol. Jul 2010;221(3):320-330. 
72. Schmitz M, Driesch C, Beer-Grondke K, Jansen L, Runnebaum IB, Durst M. Loss of 
gene function as a consequence of human papillomavirus DNA integration. Int J 
Cancer. Sep 1 2012;131(5):E593-602. 
73. Boccardo E. HPV-mediated genome instability: at the roots of cervical 
carcinogenesis. Cytogenet Genome Res. 2010;128(1-3):57-65. 
74. Thomas LK, Bermejo JL, Vinokurova S, et al. Chromosomal gains and losses in 
human papillomavirus-associated neoplasia of the lower genital tract - A systematic 
review and meta-analysis. Eur J Cancer. Sep 17 2013. 
75. Huang FY, Kwok YK, Lau ET, Tang MH, Ng TY, Ngan HY. Genetic abnormalities and 
HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet. 
Feb 2005;157(1):42-48. 
76. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J. Immortalization of 
normal human oral keratinocytes with type 16 human papillomavirus. 
Carcinogenesis. Sep 1991;12(9):1627-1631. 
 
 
